curriculum vitae - Division of Nephrology-Hypertension - UC San ...

O'Connor, Daniel T.2-26-2007CURRICULUM VITAEDaniel Thomas O'Connor, Jr., M.D.ADDRESS:Division of Nephrology-Hypertension (0838)Department of Medicine and Center for Human Genetics and GenomicsUniversity of California at San Diego (UCSD) School of Medicine & VASDHSSkaggs (SSPPS) room 42569500 Gilman DriveLa Jolla, CA 92093-0838 USATel (858)-534-0661Fax (858)-534-0626E-mail: doconnor@ucsd.eduInternet: http://medicine.ucsd.edu/hypertensionhttp://elcapitan.ucsd.edu/hyperMap building #783EDUCATION: High School: Loyola High School, Los Angeles, CAGraduated 1966, classical diplomaCollege:Loyola University, Los Angeles, CAB.S. degree, Biology, 1970Medical School: University of California at Davis,School of Medicine, Davis, CAM.D. degree, 1974HONORS/AWARDS:National Merit Scholarship finalist 1966President's Scholar, University of California 1970-1Alpha Omega Alpha (elected)1973Upjohn Achievement Award for Outstanding Clinical1974Proficiency, UC Davis School of MedicineSenior Class Award, UC Davis School of Medicine (elected) 1974Associate Investigator, Medical Research Service, 1977-9Veterans AdministrationYoung Investigator Award, National Heart, Lung & Blood 1979Institute (declined, to accept Research Assoc. Award)Research Associate, Medical Research Service, 1980-3Veterans AdministrationEstablished Investigator Award, American Heart Association1983-8Western Society for Clinical Investigation (elected) 1983Fellow, American Heart Association Council for High Blood 1983Pressure Research (elected)1

O'Connor, Daniel T.Harry Goldblatt Award for Cardiovascular Research, American 1985Heart Association Council for High Blood Pressure ResearchAmerican Society for Clinical Investigation (elected) 1986Western Association of Physicians (elected) 1986United States Patent #4,758,522: "Immunoassay of Human 1988Chromogranin A" (19 claims allowed)Young Scholar Award, American Society of Hypertension 1989Distinguished Alumnus Award, UC Davis School of Medicine 1989Clinical Investigator, Dept. of Veterans Affairs 1989-94Associate Editor, Journal of Clinical Investigation 1992-94Association of American Physicians (elected) 1995International Symposia for Chromaffin Cell Biology (ISCCB)International Advisory Board1995-presentChair, local organizing committee, ISCCB-11, San Diego 1999-2001UCSD School of Medicine Faculty Distinguished Lecturer 1998UCSD Department of Medicine PRISM lecturer 2003(Progress in the Science of Medicine)POSTGRADUATE EXPERIENCE:Intern and resident, Internal Medicine, Dept. of Medicine, UCSD 1974-1977Clinical fellow, Nephrology/Hypertension, Dept. of Medicine, UCSD 1976-1977Postdoctoral/reserch fellow, Nephrology/Hypertension, UCSD 1977-1978Sabbatical, molecular biology, UCSD 1986-1987UNIVERSITY (UCSD) APPOINTMENTS:Department of Medicine, Division of Nephrology/Hypertension, UCSDInstructor 1978-1979Assistant Professor of Medicine 1979-1985Associate Professor of Medicine 1985-1991Professor of Medicine1991-presentDirector, Hypertension, UCSD1994-presentDepartment of Pharmacology, UCSDAdjunct Professor of Pharmacology2004-presentMember, UCSD Center for Molecular Genetics1987-presentDirector, UCSD/NIH “Autonomic Pharmacodynamic Pharmacogenomics” Ctr. 2001-5Co-Director, UCSD Center for Human Genetics and Genomics 2004-presentHOSPITAL APPOINTMENTS:Staff Nephrologist, San Diego VA Medical Center1979-presentAttending Staff Physician, UCSD Medical Center1978-presentChief, Hypertension, San Diego VA Medical Center 1983-2004Acting Chief, Nephrology-Hypertension, San Diego VA Medical Center 1988-1989LICENSURE AND CERTIFICATION:National Board of Medical Examiners 1976Licensure, Board of Medical Examiners, State of California 1976Diplomate, American Board of Internal Medicine 1977Diplomate, American Board of Internal Medicine, 1980Subspecialty in Nephrology/HypertensionAmerican Society of Hypertension, Specialist in Clinical Hypertension 1999SOCIETIES AND ORGANIZATIONS:2

O'Connor, Daniel T.Alpha Omega Alpha (elected, 1973)American Federation for Clinical Research(Western Section Councillor from UC San Diego Schoolof Medicine, 1984-1987)American Society of NephrologyAmerican Society of Hypertension (charter member).ASH Specialist in Clinical Hypertension (1999-2009)Western Society for Clinical Investigation (elected, 1983)American Society for Clinical Investigation (elected, 1986)Western Association of Physicians (elected, 1987)Association of American Physicians (elected, 1995)American Physiological SocietyAmerican Society for Biochemistry and Molecular BiologyAmerican Association for the Advancement of ScienceAmerican Heart Association:Member, Council on High Blood Pressure ResearchFellow, Council on High Blood Pressure Research (elected, 1983)Member, Publications Committee, Council on High Blood PressureResearch (1986-1987)Member, Kidney CouncilNational Kidney Foundation of Southern CaliforniaMember, Research Committee: 1981; 1985-1986; 1990-1991.National Kidney FoundationProgram Committee, National Meeting, 1995Faculty member, Biomedical Sciences (formerly Physiology/Pharmacology)graduate program, UC San Diego School of Medicine (1984-present)Faculty member, Neuroscience graduate program, UC San Diego Schoolof Medicine (1985-present)Member, UC San Diego Center for Molecular Genetics (1987-Present)Editorial boards:Clinical and Experimental Hypertension (1981-90)American Journal of Kidney Diseases (1985-90)Hypertension (1990-3)Journal of Clinical Investigation (1992-7)(Associate Editor, 1992-4).International Society for Chromaffin Cell Biology (ISCCB)International Advisory Board (1995-)Chair (1999-2001).RESEARCH SUPERVISION OF STUDENTS AND FELLOWS:Medical (MD) or undergraduate student independent study (senior thesis) research atUCSD.1. Richard A. Preston, M.D. (UCSD, 1979) Prazosin and renal hemodynamics:arteriolar vasodilation during therapy of essential hypertension.2. Eric H. Sasso, M.D. (UCSD, 1980) Prazosin depression of baroreflex function inhypertensive man.3. Gerald Sugino, M.D. (UCSD, 1982) Renal perfusion is preserved duringcardioselective beta blockade with metoprolol in hypertension.4. John T. Mullen, M.D. (UCSD, 1987) Effects of non-chloride salts of potassium onblood pressure.5. Ray J. Hsiao, M.D. (UCSD, 1989) Human chromogranin A in neuroblastoma,pheochromocytoma, and renal disease.6. Dat Q. Vo, M.D. (UCSD, 1991) Candidate genes in genetic hypertension.3

O'Connor, Daniel T.7. Huan Nguyen, M.D. (UCSD, 1991) Renal clearance studies during angiotensinconverting enzyme inhibition in renal insufficiency.8. T. Teresa Dao, M.D. (UCSD, 1995). Mendelian autonomic phenotypes in humanessential hypertension.9. Joseph A. Martinez (UCSD, 1997). Kallikrein as a candidate gene in essentialhypertension.10. Elizabeth A. Tyrell, M.D. (UCSD, 1996). Early changes in glomerular filtration inhereditary hypertension.11. Regina A. Wu, M.D. (Loyola University, Chicago 1996). Central autonomiceffects of angiotensin converting enzyme inhibitors in hypertension.12. Lisa U. Yoneda, BS (UCSD, 1996). Positional cloning of hypertension genes inthe mouse.13. Vanita R. Aroda, MD (UCSD, 1998). A novel catecholamine release-inhibitorypeptide.14. Alexander Lee, MD (UCSD, 1999). Catecholamine release-inhibitory actions ofPAMP.15. Victoria Edmond, MD (UCSD, 1997). Hereditary hypertension.16. Chin K. Song, MD (UCSD, 1999). Renal kallikrein excretion in ethnically andgenetically stratified populations.17. Christopher Olonan, MD (UCSD, 2002). Novel chimeric photoproteins tomeasure chromaffin granule calcium.18. Darius Walker, BS (Clark University, 2002). Positioning human autonomicscuceptibility loci by radiation hybrid mapping.19. Omar Halawa, BS (UNC/Chapel Hill, 2004). Informatics in hereditaryhypertensive phenotypes.20. Carie Nguyen, BS (UCSD, 2003). Autonomic pharmacology of sympathomimeticamines.Graduate student (PhD) thesis research supervision at UCSD.1. Roger L. Sokoloff, for Ph.D. in Chemistry, 1982. Undergraduate: UC Berkeley.Soluble and membrane-bound dopamine-beta-hydroxylase from human andcow: structural comparisons (1979-82). Ph.D., UCSD, 1982.2. Bruce M. Gill, graduate student in Biomedical Sciences. Undergraduate: UCSD.Chromogranin structure and function (1987-92). Ph.D., UCSD, 1992.3. David J. Rozansky, graduate student (M.D./Ph.D. student) in BiomedicalSciences (1989-1993). Undergraduate: Stanford University. A glucocorticoidresponse element in the chromogranin A promoter. Ph.D., UCSD, 1993.4. Hongjiang Wu, M.D., graduate student in Biomedical Sciences (1990-4).Undergraduate: Bejing Medical University, China). The chromogranin A gene:cell type-specific expression. Ph.D., UCSD, 1994.5. Xiaobo Zhang, M.D., graduate student in Molecular Pathology (1993-4).Undergraduate: Military Medical College, China. Cell type-specific expression ofchromogranin A in somatolactotropes. M.S., UCSD, 1994.6. Carolyn V. Livsey, graduate student in Biomedical Sciences (1996-2001).Undergraduate: UC Davis. Chromogranin processing and intracellulartrafficking. PhD, UCSD, 2001.7. Surin Chitbangonsyn, M.S., graduate student, UCSD (2000-2002).Undergraduate: UCSD. Radiation hybrid library screening for hypertensioncandidate loci. M.S., UCSD, 2002.8. Ryan Fries, graduate student in Bioengineering (2003-7). Undergraduate: USC.Adrenal gene expression profiling in rodent genetic hypertension.4

O'Connor, Daniel T.9. Rany Salem, MPH, graduate student in genetic epidemiology (2003-7).Undergraduate: UCSD. Functional genomics of allelic variation at the humanchromogranin B locus (CHGB).10. Juan L. Rodriguez, graduate student in Bioinformatics (2006-). Undergraduate:MIT. Statistical genetic approaches to heredity of sympathochromaffin traits.Doctoral (PhD thesis) committees at UCSD.1. Roger L. Sokoloff, for Ph.D. in Chemistry (chair).2. Marshall Snavely, for Ph.D. in Physiology/Pharmacology.3. Victoria Boyd, for Ph.D. in Physiology/Pharmacology.4. James Moberly, for Ph.D. in Physiology/Pharmacology.5. Ken Boheler, for Ph.D. in Physiology/Pharmacology.6. Bruce M. Gill, for Ph.D. in Biomedical Sciences (chair).7. Kathy Grako, for Ph.D. in Biomedical Sciences.8. Kathy Rasmussen, for Ph.D. in Biomedical Sciences.9. David J. Rozansky, for Ph.D. in Biomedical Sciences (chair).10. Hongjiang Wu, for Ph.D. in Biomedical Sciences (chair).11. Margaret Rathouz, for Ph.D. in Biology.12. Joseph Satriano, for Ph.D. in Molecular Pathology.13. Brian Molles, for Ph.D. in Biomedical Sciences.14. Gina Schneider, for Ph.D. in Psychology (CSPP).15. Allen Swei, for Ph.D. in Biomedical Engineering.16. Camille Vogt, for PhD in Biomedical Engineering.17. Jamie Reuter, for Ph.D. in Chemistry/Biochemistry.18. David B. Young, for PhD in Chemistry/Biochemistry.19. Cornelia Bentley, for PhD in Biomedical Sciences.20. Audrey Kelleman, for PhD in Chemistry/Biochemistry.21. Li Zhang, for PhD in Chemistry/Biochemistry.22. Carolyn V. Livsey Taylor, for PhD in Biomedical Sciences (chair).23. Michael Petersen, for PhD in Biomedical Sciences.24. Sherri Liang, for PhD in Biomedical Sciences.25. Tiffany Greenwood, for PhD in Biomedical Sciences.26. Sandra B Moore, for PhD in Chemistry/Biochemistry.27. John Scheel, for PhD in Biomedical Sciences.28. David Arthur, for PhD in Biomedical Sciences.29. Martin Jirout, for PhD in Molecular Pathology.30. Ryan Fries, for PhD in Biomedical Engineering.31. Rany Salem, for PhD in Genetc Epidemiology.32. Coleman Mosley, for PhD in Bioinformatics.33. Jennifer Wessel, for PhD in Genetic Epidemiology.34. Minh- Ha Do , for PhD in Biomedical Sciences.35. Edward Duc Tran, for PhD in Bioengineering.36. Juan L. Rodriguez, for PhD in Bioinformatics.37. Matthew Zapala, for PhD in Biomedical Sciences.Faculty on sabbatical at UCSD.1. Guldborg Serck-Hanssen, Ph.D. (University of Oslo, Norway), 1982-1983; 1985.University of Bergen, Norway. Chromogranin mRNA.2. Patrick A. Sullivan, M.D. (National University of Ireland), 1986. Mallow GeneralHospital, Cork, Ireland. Control of serum potassium during exercise andangiotensin converting enzyme inhibition.5

O'Connor, Daniel T.3. Ming-Cheng Lin, M.D. (Chung San Medical College, Taiwan), 1991-1992.Chung San Medical College, Taiwan. Intermediate phenotypes in essentialhypertensive pedigrees.4. Unni Syversen, M.D. (Oslo University, Norway), 1991. Institute of CancerResearch, Trondheim University, Norway. Purification of human chromograninA.5. Kazuhiro Takekoshi, MD (University of Tsukuba, Japan), 2001-2. University ofTsukuba, Ibaraki, Japan. Molecular biology of chromogranin expression inchromaffin cells.Research/postdoctoral fellows at UCSD.1. Sanford E. Warren, M.D. (Medical College of Virginia), 1979-1980. Renalhemodynamic changes during longterm antihypertensive therapy.2. Anna P. Barg, M.D. (Ohio State University), 1979-1980. Preserved renalperfusion during treatment of essential hypertension with the beta blockernadolol.3. Coleman Mosely, M.D. (University of Maryland), 1981-1982. Enkephalins in ratpheochromocytoma: biochemical and physiologic studies.4. Keevin N. Bernstein, M.D. (University of Manitoba), 1982-1983. Humancatecholamine storage vesicle proteins.5. Robert J. Parmer, M.D. (UCSD), 1982-1983; 1984-1989. Enkephalins inchromaffin tissue and in blood pressure regulation. Molecular biology ofchromogranins.6. Matthew S. Mezger, M.D. (UC Davis), 1984-1985. Radioligand binding studieson chromogranins.7. Michiko T. Handa, M.D. (Keio University, Japan), 1986-1987. Molecular biologyof chromogranins.8. Y.-Ming Chang, M.D., 1986-1987. Radioligand binding studies onchromogranins.9. Hongjiang Wu, M.D. (Beijing Medical University), 1987-1990. Molecular biologyof dopamine-beta-hydroxylase.10. Marwan A. Takiyyuddin, M.D. (American University of Beirut), 1987-1989.Chromaffin cell secretion. Chromogranin A synthetic peptides.11. Juan A. Barbosa, M.D. (San Luis Potosi, Mexico), 1988-1990. Chromogranins--immunology and molecular biology.12. John S. Videen, M.D. (University of Arizona), 1989-1991. Interactions ofchromogranins with intragranular ligands.13. Nahida L. Eskeland, Ph.D. (Mt. Sinai, NY), 1991-1994. Chromogranin Aprocessing, and gene targeting by homologous recombination.14. Mala T. Kailasam, M.B.B.S. (Bangalore University, India), 1992-1995.Involvement of prostaglandins in blood pressure regulation in man. Autonomicintermediate phenotypes in hypertension.15. Dennis Cross, M.D. (Medical College of Wisconsin), 1992-1993. Intermediatephenotypes in hereditary hypertension.16. Kechun Tang, M.D., Ph.D. (Southern Illinois University), 1992-1996. Thechromogranin A promoter.17. Sushil K. Mahata, Ph.D. (University of Calcutta, India), 1993-1995. Nicotine andreserpine response elements in the chromogranin A promoter.18. Laurent Taupenot, Ph.D. (University of Strasbourg, France), 1995-2001. PACAPresponse elements in the chromogranin A promoter.19. Caroline M. Wong, MD (Albert Einstein, NY), 1995-6. Mineralocorticoids andkallikrein.6

O'Connor, Daniel T.20. Manjula Mahata, PhD, 1996-9 (University of Calcutta, India). Function ofbiologically active fragments of chromogranin A.21. Nicholas E. Preece, PhD (Surrey University, UK), 1996-9. NMR structures ofchromogranin A biologically active fragments.22. Ryuichi Fujii, M.D., Ph.D. (Kyushu University, Japan), 1997-1998. Transgenicapproaches to chromogranin A.23. Lucy M. Miller, M.D. (University of Santo Amaro Medical School, Brazil), 1997-8.Glomerular filtration in subjects at genetic risk of hypertension.24. Melissa M. Go, M.D. (University of the Philippines), 1998-9. Adrenergic receptorpolymorphisms in human hypertension.25. Peter E. Cadman, M.D. (Columbia University), 2000-4. Actions of chromaffingranule peptides in vivo.26. Kimberly L. Harper, M.D. (Washington University, St. Louis), 2000-2. Biologicallyactive chromogranin/secretogranin peptides in cultured cells.27. Clifford Wong, M.D. (UCSD), 2001-2. A novel polymorphism in the angiotensin IIreceptor promoter.28. Susan Nguyen, MD (UCSD), 2002-4. RNA silencing in control of chromaffin cellgene expression.29. Rubin Chandran, MD (Washington University, St. Louis), 2002-3.Pharmacogenetic approaches to angiotensin II blockade.30. Fangwen Rao, MD (North Sichuan Medical College, China), 1999-2004.Hereditary auronomic phenotypes in human twins.31. Danuta King, MD (Harvard University), 2002-4. Pharmacogenetics of presynatpicadrenergic agonist responses in a regional circulatory bed.32. Lian Zhang, M.D. (Chongqing Medical University, China), 2002-4. Tyrosinehydroxylase polymorphisms and human autonomic function.33. Clayton Smiley, MD (University of Chicago), 2003-4. Heritability of renal kallikreinexcretion in human twins.34. Elizabeth O. Lillie, PhD (USC, 2004), 2004-7. Twin studies of heritability inautonomic function35. Nicholas Rowder, MD (Baylor University), 2004-6. Twin studies of uric acidmetabolism.36. Yuqing Chen, MD, PhD (Peking University), 2005-. Genomics of renal failure.37. Kuixing Zhang, MD, PhD (Shanghai 2 nd Medical University), 2005-. Genomics ofhypertension.38. Maple Fung, M.D. (UCSD). 2006-. Heredity and cardio-renal disease risk.AWARDS WON BY TRAINEES.1. Robert J. Parmer, M.D. (UCSD). NIH/NHLBI Physician Scientist Award, 1984-1989.2. Robert J. Parmer, M.D. (UCSD). Research Associate Award, Department ofVeterans Affairs, 1989-1993.3. Robert J. Parmer, M.D. (UCSD). Henry Christian Award for Clinical Research,American Federation for Clinical Research, 1991.4. Hongjiang Wu, M.D. (Beijing Medical University, China). National KidneyFoundation individual postdoctoral research fellowship, 1988-1990.5. Keevin N. Bernstein, M.D. (University of Manitoba, Canada). National KidneyFoundation individual postdoctoral research fellowship, 1982-1983.6. Marwan A. Takiyyuddin, M.D. (American University, Beirut). National KidneyFoundation / American Society of Nephrology Young Investigator Award, 1989-91 (declined, to accept NIH FIRST award).7

O'Connor, Daniel T.7. Marwan A Takiyyuddin, M.D. (American University, Beirut). NIH/NHLBI FIRST(First Independent Research Support After Training) Award, 1989-1994.8. John S. Videen, M.D. (University of Arizona). NIH/NHLBI Physician ScientistAward, 1991-1996.9. Lucy Eskeland, Ph.D. (Mt. Sinai, NY). National Kidney Foundation individualpostdoctoral research fellowship, 1992-1994.10. Bruce M. Gill, Ph.D. (UCSD). Banting and Best Fellowship, Department ofMedical Research, University of Toronto, Ontario, Canada, 1992.11. Hongjiang Wu, M.D. (Beijing Medical University). National Institutes of Healthfellowship, 1993-1995.12. Kechun Tang, M.D., Ph.D. (Southern Illinois University). National KidneyFoundation of Southern California fellowship, 1993-1994.13. Robert J. Parmer, M.D. (UCSD). American Heart Association EstablishedInvestigator Award, 1994-1999.14. T. Teresa Dao, M.D. (UCSD). Merck Young Investigator Award, American HeartAssociation Council for High Blood Pressure Research, 1994.15. Kechun Tang, M.D., Ph.D. (Southern Illinois University). National KidneyFoundation individual postdoctoral fellowship. 1994-1996.16. Joseph A. Martinez, MD (UCSD). American Federation for Clinical Researchtrainee award for outstanding abstract by a student in the Hypertension session,Western Section meeting, 1995.17. T. Teresa Dao, M.D. (UCSD). Joseph Stokes Memorial Award, UCSD, 1995.Hamburger Medical Research Award, UCSD, 1995 (runner-up).18. Hongjiang Wu, M.D., Ph.D. (UCSD). Merck Young Investigator Award, AmericanHeart Association Council for High Blood Pressure Research, 1995.19. Kechun Tang, M.D., Ph.D. (Southern Illinois University). Marion Merrell Dowfellowship award finalist, American Heart Association Council for High BloodPressure Research, 1995.20. Laurent Taupenot, Ph.D. (Strasbourg University, France). National KidneyFoundation of Southern California fellowship, 1995-1996.21. Laurent Taupenot, Ph.D. (Strasbourg University, France). National KidneyFoundation individual postdoctoral fellowship, 1996-1999.22. Laurent Taupenot, Ph.D. (Strasbourg University, France). American HeartAssociation, California affiliate postdoctoral Fellowship, 1996-1998. Declined, toaccept NKF fellowship.23. Victoria Edmond, MD, UCSD '97. National Medical Fellowship, 1996-1997.24. Sushil K. Mahata, Ph.D. (University of Calcutta, India). NIH FIRST (R29)award, 1997-2002.25. Melissa M. Go, M.D. (University of the Philippines). American Society ofHypertension/Hoechst fellowship, 1998-9.26. Carolyn V. Livsey Taylor, PhD (UCSD). Merck Young InvestigatorAward. American Heart Association Council for High Blood PressureResearch, 1998.27. Carolyn V. Livsey Taylor, PhD (UCSD). American Heart Association,Western States Affiliate, pre-doctoral fellowship, 1999-2001.28. Peter E. Cadman, M.D. (Columbia University). American Society ofHypertension/Hoechst fellowship, 2000-1.29. Laurent Taupenot, PhD (Strasbourg University, France). NIH K01 younginvestigator career development award, 2001-6.30. Peter E. Cadman, M.D. (Columbia University). NIH K23 careerdevelopment award, 2002-7.8

O'Connor, Daniel T.31. Sushil K. Mahata, Ph.D. (University of Calcutta, India). VA Merit Reviewgrant, 2002-2005, 2005-2010.32. Danuta King, MD (Harvard Medical School). National KidneyFoundation/AMGEN western region nephrology felllows’ research forum.First place award, 2004.33. Sushil K. Mahata, Ph.D. (University of Calcutta, India). NIH R01 award,2005-2010.34. Laurent Taupenot, PhD (Strasbourg University, France). NIH PPG award,2005-2010.35. Elizabeth O. Lillie, Ph.D. (Universitry of Southern California). NationalKidney Foundation individual postdoctoral fellowship, 2005-2007.36. Fangwen Rao, MD (North Sichuan Medical College, China). InternationalSociety of Nephrology travel award, 2005.37. Yuqing Chen, MD, PhD (Peking University, China). International Societyof Nephrology research fellowship, 2005-6.38. Maple Fung, MD (UCSD). National Kidney Foundation/AMGEN westernregion nephrology felllows’ research forum. First place award, 2007.JOURNAL, SCIENTIFIC MEETING AND GRANTING AGENCY REVIEWER.Clinical and Experimental Hypertension (editorial board, 1981-90)Regulatory PeptidesJournal of the American Medical AssociationJournal of Clinical PharmacologyAnalytical BiochemistryJournal of Cardiovascular PharmacologyHypertension (editorial board, 1990-1993)Archives of Internal MedicineAmerican Journal of Kidney Diseases (editorial board, 1985-90)New England Journal of MedicineJournal of Clinical Endocrinology & MetabolismCirculationScienceJournal of Histochemistry and CytochemistryHistochemistry JournalBiochemistryJournal of Biological ChemistryMolecular EndocrinologyEndocrinologyJournal of Clinical Investigation (Associate Editor, 1992-1994)Veterans Administration Medical Research Service, National and LocalEndocrinology study section (ad hoc), 1995-6, 2001.National Institutes of HealthNHLBI site visitor, 1991.Experimental Cardiovascular Sciences (ECS) study section (ad hoc), 1997.Cardiovascular and Renal (CVB) Study Section (ad hoc), 1998-.Connaught Committee, University of TorontoNational Kidney Foundation of Southern California (Research Committee,1981; 1985-1986; 1990-1991)National Kidney Foundation program committee, national meeting, 1994-1995.Hereditary human hypertension session organizer, 1995.American Federation for Clinical Research (Western Section)Renal/Hypertension session, 19839

O'Connor, Daniel T.Hypertension/Clinical Pharmacology session coordinator, 1984Hypertension/Clinical Pharmacology session coordinator, 1992American Federation for Clinical Research (national meeting)Hypertension session, 1983Hypertension session, 1991American Society of NephrologyHypertension session coordinator, 1983Prostaglandin/Kinin/Renal Hormone session, 1984Hypertension session coordinator, 1986Hypertension session, 1988Hypertension session, 1989Endothelium/vasoactive hormone section, 1992.Hypertension short course organizer/chair, 1996.Intracellular protein traffic session organizer/chair, 1999.Hypertension session, 2001.American College of Chest PhysiciansHypertension session coordinator, 1988American Society of HypertensionEndocrine/hypertension session, 1991Endocrine/hypertension session, 1992Clinical Hypertension Specialist Board Review question submissions, 2000.American Heart AssociationCardiovascular Regulation Study Section (national), 1992.California Affiliate, Research Committee, 1991-1992Abstract reviewer, autonomic session, 2000.Abstract reviewer, Council for High Blood Pressure Research, 2001.Council on High Blood Pressure Research, Education Committee, 2001-.Interamerican Society of HypertensionLocal organizing and program committee, 1993.International Society for Chromaffin cell Biology (ISCCB), 1983-.International Advisory Board (1995-)Local Organizing Committee for 2001 meeting (chair), 1999-2001.American College of Physicians.Medical Knowledge Self Assessment Program (MKSAP),Nephrology/Hypertension, 1996-8.10

O'Connor, Daniel T.A. PUBLISHED WORK.I. Original articles.19761. Rubin RT, Poland R, O'Connor DT, Gouin P, Tower B: Selectiveneuroendocrine effects of low-dose haloperidol in normal adult men.Psychopharmacol 47:135-140, 1976.2. Gumprecht T, O'Connor DT, Rearden A, Wolf PL: Negative anion gap in ayoung adult with multiple myeloma. Clin Chem 22:1920-21, 1976.19783. O'Connor DT, Stone RA: Hyperchloremia and negative anion gap associatedwithpolymixin B administration. Arch Int Med 138:478-480, 1978.4. Warren S, O'Connor DT, Steinberg SM: Recirculation: a uremic syndromecomplicating the use of prosthetic arterio- venous fistulas for hemodialysis. JDialysis 2:251-259, 1978.5. O'Connor DT, Weisman MH, Fierer J: Activation of the alternate complementpathway in Staphylococcus aureus infective endocarditis and its relationship tothrombocytopenia, coagulation abnormalities and acute glomerulonephritis. ClinExp Immunol 34:179-87, 1978.6. Mitas JA, O'Connor DT, Stone RA: Hypertension in renal insufficiency: A majortherapeutic problem. Postgrad Med 64:113-120, 1978.19797. O'Connor DT, Frigon RP, Stone RA: Human pheochromocytoma dopaminebeta-hydroxylase: purification and molecular parameters of the tetrameter.Molec Pharmacol 16: 529-538, 1979.8. Preston RA, O'Connor DT, Stone RA: Prazosin and renal hemodynamics:arteriolar vasodilation during therapy of essential hypertension. J CardiovascPharmacol 1:277-286, 1979.9. Cohen IM, O'Connor DT, Preston RA, Stone RA: Reduced renovascularresistance on clonidine. Clin Pharmacol Ther 26:572-577, 1979.10. O'Connor DT, Preston RA, Sasso E: Renal perfusion changes during treatmentof essential hypertension: prazosin vs. propranolol. J Cardiovasc Pharmacol1(Suppl.): S38-S42, 1979.198011. Warren SE, O'Connor DT: Does a renal vasodilator system mediate racialdifferences in essential hypertension? Am J Med 69:425-429, 1980.12. Warren SE, O'Connor DT: Hyperkalemia resulting from captopril administration.J Am Med Assoc 244:2551-2552, 1980.13. Warren SE, Viewig WVR, O'Connor DT: Sympathetic nervous system activityduring sodium restriction in essential hypertension. Clin Cardiol 3:348-351, 1980.14. Warren SE, Cohen IM, Barg AP, O'Connor DT: Guanabenz andhydrochlorothiazide for the treatment of essential hypertension: enhanced renalperfusion. Curr Ther Res 28: 530-534, 1980.15. O'Connor DT, Preston RA, Sasso EH: Cambios de irrigacion renal durante altratamiento de la hipertension arterial esencial: prazosin en comparison conpropranolol. Cardiol 66(Suppl.):69-73, 1980.16. Hsueh WA, Carlson EJ, O'Connor DT, Warren SE: Renin requires a structuralalteration prior to activation by renal kallikrein. J Clin Endocrinol Metab 51:942-944, 1980.198111

O'Connor, Daniel T.17. O'Connor DT, Preston RA, Mitas JA, Frigon RP, Stone RA: Urinary kallikreinactivity and renal vascular resistance in the antihypertensive response to thiazidediuretics. Hypertension 3:139-147, 1981.18. Olshan AR, O'Connor DT, Preston RA, Frigon RP, Stone RA: Involvement ofkallikrein in the antihypertensive response to furosemide in essentialhypertension. J Cardiovasc Pharmacol 3:161-167, 1981.19. Cohen IM, O'Connor DT, Preston RA, Stone RA: Long-term clonidine effectsupon autonomic function in essential hypertensive man. Eur J Clin Pharmacol19:25-32, 1981.20. Warren SE, O'Connor DT, Cohen IM. Mitas JA: Renal hemodynamic changesduring long-term antihypertensive therapy. Clin Pharmacol Ther 29:310-317,1981.21. Warren SE, O'Connor DT: The antihypertensive mechanism of sodiumrestriction. J Cardiovasc Pharmacol 3:781-790, 1981.22. Frigon RP, O'Connor DT, Levine GL: Human dopamine beta-hydroxylase.Comparison of the enzyme from plasma, adrenal medulla, andpheochromocytoma by radioimmunoassay. Molec Pharmacol 19:444-450, 1981.23. Schuckit MA, O'Connor DT, Duby J, Vega R, Moss M: Dopamine betahydroxylaseactivity levels in men at high risk for alcoholism, and controls. BiolPsychiatr 16:1067-1075, 1981.24. Mitas JA, O'Connor DT, Stone RA: Evaluation of the neurogenic component ofhypertension associated with dialysis and renal insufficiency. ASAIO Journal4:56-60, 1981.198225. O'Connor DT, Barg A, Duchin K: Preserved renal perfusion during treatment ofessential hypertension with the beta blocker nadolol. J Clin Pharmacol 22:187-195, 1982.26. Sasso EH, O'Connor DT: Prazosin depression of baroreflex function inhypertensive man. Eur J Clin Pharmacol 22:7-14, 1982.27. O'Connor DT, Frigon RP, Sokoloff RL: Human catecholamine storage vesicleproteins. Clin Exp Hypertension A4(4&5):563-575, 1982.28. Snavely MD, Motulsky HJ, O'Connor DT, Ziegler MG, Insel P: Adrenergicreceptors in human and experimental pheochromocytoma. Clin ExpHypertension A4:829-848, 1982.29. O'Connor DT, Preston RA: Propranolol effects upon autonomic function inhypertensive man. Clin Cardiol 5: 340-346, 1982.30. O'Connor DT, Barg AP, Amend W, Vincenti F: Urinary kallikrein excretion afterrenal transplantation: relationship to hypertension, graft source and renalfunction. Am J Med 73: 475-481, 1982.31. Olshan AR, O'Connor DT, Cohen IM, Mitas JA, Stone RA: Hypertension in adultonset diabetes mellitus: abnormal renal hemodynamics and endogenousvasoregulatory factors. Am J Kidney Dis 2:271-280, 1982.32. O'Connor DT, Preston RA: Urinary kallikrein activity, renal hemodynamics andrenal electrolyte handling after beta blockade with propranolol in hypertension.Hypertension 4: 742-749, 1982.33. Morrison JH, Foote SL, O'Connor DT, Bloom FE: Laminar, tangential andregional organization of the noradrenergic innervation of monkey cortex:dopamine-beta-hydroxylase immunohistochemistry. Brain Res Bull 9:309-319,1982.34. O'Connor DT: Response of the renal kallikrein-kinin system, intravascularvolume and renal hemodynamics to sodium restriction and diuretic treatment inessential hypertension. Hypertension 4 (Suppl. III):III72-III78, 1982.35. Griswold W, McNeal R, O'Connor DT, Reznick V, Mendoza S: Oral convertingenzyme inhibitor in malignant hypertension. Arch Dis Child 57:235-237, 1982.198312

O'Connor, Daniel T.36. Motulsky HJ, O'Connor DT, Insel P: Platelet alpha adrenergic receptors arenormal in untreated and treated hypertensive man. Clin Sci Mol Med 64:265-272, 1983.37. O'Connor DT, Gochman N: Lactic dehydrogenase activity in humanpheochromocytoma. J Am Med Assoc 249:383-385, 1983.38. O'Connor DT, Frigon RP, Deftos LJ: Immunoreactive calcitonin incatecholamine storage vesicles from human pheochromocytoma. J ClinEndocrinol Metab 56:582-585, 198339. Olshan AR, O'Connor DT, Cohen IM, Mitas JA, Stone RA: Baroreflexdysfunction in adult onset diabetics with hypertension. Am J Med 74:233-242,1983.40. Warren SE, O'Connor DT, Cohen IM: Autonomic and baroreflex function aftercaptopril in hypertension. Am Heart J 105:1002-1008, 1983.41. Gozes I, O'Connor DT, Bloom FE: Sequestration of vasoactive intestinalpolypeptide in pheochromocytoma chromaffin granules: a possible highmolecular weight precursor. Regulatory Peptides 6:111-119, 1983.42. O'Connor DT, Levine GL, Frigon RP: Homologous radioimmunoassay ofhuman plasma dopamine beta-hydroxylase: analysis of homospecific activity,circulating plasma pool and intergroup differences based on race, bloodpressure, and cardiac function. J Hypertension 1:227-233, 1983.43. Snavely M, Mahan LC, O'Connor DT, Insel PA: Selective down regulation ofadrenergic receptor subtypes in tissues from rats with pheochromocytoma.Endocrinol 113:354-361, 1983.44. Bernstein KN, Barg AP, O'Connor DT: Nadolol: Evidence for sympatheticnerve inhibition by a beta blocker in essential hypertension. J Hypertension1:291-296, 1983.45. O'Connor DT: Chromogranin: widespread immunoreactivity in polypeptidehormone producing tissues and in serum. Regulatory Peptides 6:263-280, 1983.46. O'Connor DT: Renal blood flow during nadolol administration. (Letter to theEditor) N Engl J Med 308:49, 1983.47. O'Connor DT, Burton DG, Deftos LJ: Chromogranin A: Immunohistologyreveals its universal occurrence in normal polypeptide hormone producingendocrine glands. Life Sci 33:1657-1663, 1983.48. O'Connor DT, Burton DG, Deftos LJ: Immunoreactive chromogranin A indiverse polypeptide hormone producing human tumors and normal endocrinetissues. J Clin Endocrinol Metab 57:1084-1986, 1983.198449. Sugino G, Barg AP, O'Connor DT: Renal perfusion is preserved duringcardioselective beta blockade with metoprolol in hypertension. Am J Kidney DisIII:357-361, 1984.50. O'Connor DT, Frigon RP, Sokoloff RL: Human chromogranin A: purification andcharacterization from catecholamine storage vesicles of pheochromocytoma.Hypertension 6:2-12, 1984.51. O'Connor DT, Frigon RP: Chromogranin A, the major catecholamine storagevesicle soluble protein: multiple size forms, subcellular storage and regionaldistribution in chromaffin and nervous tissue elucidated by radioimmunoassay. JBiol Chem 259:3237-3247, 1984.52. Bernstein KN, O'Connor DT: Antiadrenergic antihypertensive drugs: theireffects on renal function. Ann Rev Pharmacol Toxicol 24:105-120, 1984.53. Serck-Hanssen G, O'Connor DT: Immunological identification andcharacterization of chromogranins coded by poly (A)-mRNA from bovine adrenalmedulla and pituitary gland and human phaeochromocytoma. J Biol Chem259:11597-11600, 1984.54. O'Connor DT, Parmer RJ, Deftos LJ: Chromogranin A: studies in the endocrinesystem. Trans Assoc Am Physicians 97:242-250, 1984.55. O'Connor DT: Chromogranin A: Implications for hypertension. J Hypertension2(Suppl. 3):147-150, 1984.13

O'Connor, Daniel T.56. O'Connor DT, Mosley C, Cervenka J, Bernstein K: Contrasting renalhemodynamic responses to the angiotensin converting enzyme inhibitor enalapriland the beta adrenergic antagonist metoprolol in essential hypertension. JHypertension 2(Suppl.):89-92, 1984.57. O'Connor DT, Bernstein KN: Radioimmunoassay of chromogranin A in plasmaas a measure of exocytotic sympathoadrenal activity in normal subjects andpatients with pheochromocytoma. N Engl J Med 311:764-770, 1984. (topic ofeditorial in same issue)58. Mosley C, O'Connor DT, Taylor A, Slutsky R, Cervenka J: Comparative effectsof antihypertensive therapy with guanabenz and propranolol on renal vascularresistance and left ventricular mass. J Cardiovasc Pharmacol 6:s757-s761,1984.198559. Parmer R, Mosley C, O'Connor DT: Enkephalins in pheochromocytoma: studiesin a rat model. Clin Exp Hypertension A7:483-512, 1985.60. Sokoloff RL, Frigon RP, O'Connor DT: Dopamine beta-hydroxylase: structuralcomparisons of membrane bound versus soluble forms from adrenal medullaand pheochromocytoma. J Neurochem 44:441-450, 1985.61. Kruggel W, O'Connor DT, Lewis R: The amino terminal sequences of bovineand human chromogranin A and secretory protein I are identical. BiochemBiophys Res Commun 127:380-383, 1985.62. O'Connor DT: Plasma chromogranin A: Initial studies in human hypertension.Hypertension 7:I76-I79, 1985.198663. O'Connor DT, Deftos LJ: Secretion of chromogranin A by peptide producingendocrine neoplasms. N Engl J Med 314:1145-1151, 1986.64. O'Connor DT, Levy B, Smith D, Winer N: Initial combination therapy forhypertension: efficacy and metabolic advantages. Curr Ther Res 39:195-207,1986.65. Deftos LJ, Murray S, Burton DG, Parmer RJ, O'Connor DT: A clonedchromogranin A cDNA detects a 2.3 kb mRNA in diverse neuroendocrinetissues. Biochem Biophys Res Commun 137:418-423, 1986.66. Sobol RE, O'Connor DT, Addison J, Suchocki K, Royston I, Deftos LJ: Elevatedserum chromogranin A concentrations in small-cell lung carcinoma. Ann Int Med105:698-700, 1986.198767. Lauweryns JM, Van Ranst L, Lloyd R, O'Connor DT: Chromogranin inbronchopulmonary neuroendocrine cells: Immunocytochemical detection inhuman, monkey and pig respiratory mucosa. J Histochem Cytochem 35:113-118, 1987.68. Eiden L, Huttner W, Mallet J, O'Connor DT, Winkler H, Zanini A: Anomenclature proposal for the chromogranin/secretogranin proteins. Neurosci21:1019-1021, 1987.69. Murray S, Deaven LL, Burton DG, O'Connor DT, Mellon P, Deftos LJ: The genefor human chromogranin A is located on chromosome 14. Biochem Biophys ResCommun 142:141-146, 1987.70. Deftos LJ, Bjornsson B, Burton DG, O'Connor DT, Copp DH: Chromogranin Ais present in and released by fish endocrine tissue. Life Sci 40:2133-2136, 1987.71. Schober M, Fischer-Colbrie R, Schmid KW, Bussolati G, O'Connor DT, WinklerH: Comparison of chromogranins A, B, and secretogranin II in human adrenalmedulla and pheochromocytoma. Lab Invest 57:385-391, 1987.72. O'Connor DT, Strause L, Saltman P, Parmer RJ, Cervenka J: Serum zinc isunaffected by effective captopril treatment of hypertension. J Clin Hypertension3:405-408, 1987.14

O'Connor, Daniel T.73. Kemper CM, O'Connor DT, Westlund KN: Immunocytochemical localization ofdopamine-beta-hydroxylase in neurons of the human brain stem. Neurosci23:981-989, 1987.198874. Parmer RJ, O'Connor DT: Enkephalins in human phaeochromocytoma:localization in immunoreactive high molecular weight form to the soluble core ofchromaffin granules. J Hypertension 6:187-198, 1988.75. Sullivan PA, Dineen M, Cervenka J, O'Connor DT: Effects of fosinopril, a oncedailyangiotensin-converting enzyme inhibitor, on resting and exercise-inducedchanges of blood pressure, hormonal variables, and plasma potassium inessential hypertension. Am J Hypertension 1:280S-283S, 1988.76. Powers RE, Struble RG, Casanova MF, O'Connor DT, Kitt CA, Price DL:Innervation of human hippocampus by noradrenergic systems: normal anatomyand structural abnormalities in aging and in Alzheimer's disease. Neuroscience25:401-417, 1988.77. Deftos LJ, Linnoila RI, Carney DN, Burton DW, Leong SS, O'Connor DT, MurrayWW, Gazdar AF: Demonstration of chromogranin A in human neuroendocrinecell lines by immunohistology and immunoassay. Cancer 62:92-97, 1988.78. Weiler R, Fischer-Colbrie R, Schmid KW, Feichtinger H, Bussolati G, GrimeliusL, Krisch K, Kerl H, O'Connor DT, Winkler H: Immunological studies on theoccurrence and properties of chromogranin A and B and secretogranin II inendocrine tumors. Am J Surg Pathol 12:877-884, 1988.79. O'Connor DT, Subramani S: Do transcriptional enhancers also augment DNAreplication? Nucl Acids Res 16(23):11207-11222, 1988.80. Simonsson M, Ericksson S, Hakanson R, Lind T, Lonroth H, Lundell L,O'Connor DT, Sundler F: Endocrine cells in the human oxyntic mucosa: ahistochemical study. Scand J Gastroenterol 23:1089-1099, 1988.198981. Takiyyuddin MA, Cervenka JH, Dinh TQ, Witztum J, O'Connor DT: Selectivealpha-blockade versus angiotensin-converting enzyme inhibition as initialantihypertensive therapy. Effects on circulating lipoproteins. Am J Med 86(S1B):32-35, 1989.82. Gifford RW, Kirkendall W, O'Connor DT, Weidman W: Office evaluation ofhypertension. A statement for health professionals by a writing group of theCouncil for High Blood Pressure Research, Am Heart Assn. Hypertension13:283-293, 1989. Circulation 79:721-731, 1989.83. Powers RE, O'Connor DT, Price DL: Noradrenergic systems in humancerebellum. Brain Research 481:194-199, 1989.84. Sullivan PA, Cervenka J, O'Connor DT, Dineen M: Fosenopril, an angiotensinconverting enzyme inhibitor, and propranolol: comparative effects at rest andduring exercise on blood pressure, hormonal variables and plasma potassium inessential hypertension. Cardiovasc Drugs & Therapy 3:57-62, 1989.85. Parmer RJ, Koop AH, Handa MT, O'Connor DT: Molecular cloning ofchromogranin A from rat pheochromocytoma cells. Hypertension 14:435-44,1989.86. Nanes MS, O'Connor DT, Marx SJ: Plasma chromogranin A in primaryhyperparathyroidism. J Clin Endo Metab 69:950-5, 1989.87. Deftos LJ, O'Connor DT, Wilson CB, Fitzgerald PA: Human pituitary tumorssecrete chromogranin A. J Clin Endo Metab 68:869-72, 1989.88. Dimsdale JE, O'Connor DT, Ziegler M, Mills P: Does chromogranin A respond toshort-term mild physiologic challenge? Neuropsychopharmacology. 2:237-40,1989.89. O'Connor DT, Pandian MR, Carlton E, Cervenka JH, Hsiao RJ: Rapidradioimmunoassay of circulating chromogranin A: in vitro stability, exploration ofthe neuroendocrine character of neoplasia, and assessment of the effects oforgan failure. Clin Chem 35:1631-7, 1989.15

O'Connor, Daniel T.90. Jengeleski CA, Powers RE, O'Connor DT, Price DL: Noradrenergic innervationof human pineal gland: abnormalities in aging and Alzheimer's disease. BrainResearch 481:378-82, 1989.199091. Polikar R, Kennedy B, Ziegler M, O'Connor DT, Smith J, Nicod P. Plasmanorepinephrine kinetics, dopamine-beta-hydroxylase, and chromogranin A inhypothyroid patients before and following replacement therapy. J Clin EndoMetab 70: 277-281, 1990.92. Takiyyuddin MA, Cervenka JH, Hsiao RJ, Barbosa JA, Parmer RJ, O'ConnorDT. Chromogranin A: storage and release in hypertension. Hypertension 15:237-246, 1990.93. Takiyyuddin MA, Cervenka JH, Sullivan PA, Pandian MR, Barbosa JA,O'Connor DT: Is physiologic sympathoadrenal catecholamine releaseexocytotic in humans? Circulation 81:185-195, 1990.94. Carmichael SW, Stoddard SL, O'Connor DT, Yaksh TL, Tyce GM: Thesecretion of catecholamines, chromogranin A and neuropeptide Y from theadrenal medulla of the cat via the adrenolumbar vein and thoracic duct: differentanatomic routes based on size. Neuroscience 34:433-440, 1990.95. Hsiao RJ, Mezger MS, O'Connor DT: Chromogranin A in uremia: progressiveretention of immunoreactive fragments. Kidney International 37:955-964, 1990.96. Parmer RJ, Cervenka JH, Stone RA, O'Connor DT: Autonomic function inhypertension: are there racial differences? Circulation 81:1305-1311, 1990.97. Ziegler MG, Kennedy B, Morrissey E, O'Connor DT: Norepinephrine clearance,chromogranin A and dopamine-beta-hydroxylase in renal failure. KidneyInternational 37:1357-1362, 1990.98. Hsiao RJ, Seeger RC, Yu AL, O'Connor DT: Chromogranin A in children withneuroblastoma: serum concentration parallels disease stage and predictssurvival.J Clin Invest 85:1555-1559, 1990.99. Stabile BE, Howard TJ, Passaro E, O'Connor DT: Source of plasmachromogranin A elevation in gastrinoma patients. Arch Surg 125:451-3, 1990.100. Wu HJ, Parmer RJ, Koop AH, Rozansky DJ, O'Connor DT: Molecular cloning,structure and expression of dopamine beta-hydroxylase from bovine adrenalmedulla. J Neurochem 55:97-105, 1990.101. Takiyyuddin MA, Cervenka JH, Pandian MR, Stuenkel CA, Neumann HPH,O'Connor DT: Neuroendocrine sources of chromogranin A in normal man:clues from selective stimulation of endocrine glands. J Clin Endo Metab 71:360-9, 1990.102. Hsiao RJ, Neumann HPH, Parmer RJ, Barbosa JA, O'Connor DT:Chromogranin A in familial pheochromocytoma: diagnostic screening value,prediction of tumor mass, and post-resection kinetics indicating twocompartmentdistribution. Amer J Med 88:607-613, 1990.103. Mullen JT, O'Connor DT: Potassium effects on blood pressure: is theconjugate anion important? J Human Hypertension 4:589-96, 1990.104. Lahr G, Heiss C, Mayerhofer A, Schilling K, Parmer RJ, O'Connor DT, Gratzl M:Chromogranin A in the olfactory system of the rat. Neuroscience 39:605-611,1990.105. Powers RE, O'Connor DT, Price DL: Noradrenergic innervation of humaninferior olivary complex. Brain Research 523:151-5, 1990.1991106. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O'Connor DT: Chromogranin A storageand secretion: sensitivity and specificity for the diagnosis of pheochromocytoma.Medicine 70:33-45, 1991.107. Barbosa JA, Gill BM, Takiyyuddin MA, O'Connor DT: Chromogranin A:posttranslational modifications in secretory granules. Endocrinology 128:174-190, 1991.16

O'Connor, Daniel T.108. Takiyyuddin MA, Neumann HPH, Cervenka JH, Kennedy B, Dinh TQ, ZieglerMG, Baron AD, O'Connor DT: Ultradian variations of chromogranin A inhumans. Am J Physiol 30:r939-r944, 1991.109. Takiyyuddin MA, Baron AD, Cervenka JH, Barbosa JA, Neumann HPH, ParmerRJ, Sullivan PA, O'Connor DT: Suppression of chromogranin A release fromneuroendocrine sources in man: pharmacological studies. J Clin Endo Metab72:616-622, 1991.110. Gill BM, Barbosa JA, Dinh TQ, Garrod S, O'Connor DT: Chromogranin B:isolation from pheochromocytoma, N-terminal sequence, tissue distribution andsecretory vesicle processing. Regul Peptides 33:223-35, 1991.111. Shults CW, O'Connor DT, Baird A, Hill R, Goetz CG, Watts RL, Klawans HL,Carvey PM, Bakay RM, Gage FH, U HS: Clinical improvement in Parkinsonianpatients undergoing adrenal to caudate transplantation is not reflected bychromogranin A or basic fibroblast growth factor in ventricular fluid. Exp Neurol111:276-81, 1991.112. Ito MK, O'Connor DT: Skin pretreatment and the use of transdermal clonidine.Amer J Med 91(1A):1A-42S-1A-49S, 1991.113. Wand GS, Takiyyuddin M, O'Connor DT, Levine MA: A proposed role forchromogranin A as a glucocorticoid-responsive inhibitor of proopiomelanocortinsecretion. Endocrinology 128:1345-51, 1991.114. McGrath-Linden SJ, Johnston CF, O'Connor DT, Shaw C, Buchanon KD:Pancreastatin immunoreactivity in human carcinoid disease. Regul Peptides33:55-70, 1991.115. Wu HJ, Rozansky DJ, Parmer RJ, Gill BM, O'Connor DT: Structure andfunction of the chromogranin A gene: clues to evolution and tissue-specificexpression. J Biol Chem 266:13130-4, 1991.116. Rogers PJ, Tyce GM, Weinshilboum RM, O'Connor DT, KR Bailey, Bove AA:Catecholamine metabolic pathways and exercise training: plasma and urinarycatecholamines, metabolic enzymes, and chromogranin A. Circulation 84:2346-56, 1991.117. O'Connor DT, Klein RL, Thureson-Klein AK, Barbosa JA: Chromogranin A:localization and stoichiometry in large dense core catecholamine storagevesicles from sympathetic nerve. Brain Research 567:188-196, 1991.1992118. Videen JS, Mezger MS, Chang YM, O'Connor DT: Calcium and catecholamineinteractions with adrenal chromogranins: comparison of driving forces in bindingand aggregation. J Biol Chem 267:3066-73, 1992.119. Van Kammen DP, Peters J, Yao J, Neylan T, Beuger M, Pontius E, O'ConnorDT: CSF chromogranin A-like immunoreactivity in schizophrenia: assessment ofclinical and biochemical relationships. Schizophrenia Research 6:31-9, 1992.120. Gill BM, Barbosa JA, Hogue-Angeletti R, Varki N, O'Connor DT: ChromograninA epitopes: clues from synthetic peptides and peptide mapping. Neuropeptides21:105-18, 1992.121. Blind E, Schmidt-Gayk H, Sinn H-P, O'Connor DT, Raue F: Chromogranin A asa tumor marker in medullary thyroid carcinoma. Thyroid 2:5-10, 1992.122. Van Kammen DP, O'Connor DT, Neylan TC, Mouton A, Gurklis JA, GilbertsonMW, Peters JL. CSF chromogranin A-like immunoreactivity in schizophrenia:relationships with REM latency and slow wave sleep. Psychiatry Research42:53-63, 1992.123. Dimsdale JE, O'Connor DT, Ziegler M, Mills P: Chromogranin A correlates withnorepinephrine release rate. Life Sci 51:519-25, 1992.124. Syversen U, Waldum HL, O'Connor DT: Rapid, high-yield isolation of humanchromogranin A from chromaffin granules of pheochromocytomas.Neuropeptides 22:235-240, 1992.125. Bender H, Maier A, Wiedenmann B, O'Connor DT, Messner K, Schmidt-Gayk H:Immunoluminometric assay of chromogranin A in serum with commerciallyavailable reagents. Clin. Chem. 38: 2267-2272, 1992.17

O'Connor, Daniel T.126. Sullivan PA, Grosch C, Lawless D, O'Connor DT: Short-term strenuous exercisetraining: effects on blood pressure and hormonal levels in mild hypertension. Ir JMed Sci 161:666-9, 1992.1993127. Parmer RJ, Miles LA, Xi XP, Gill BM, Wu HJ, O'Connor DT: Processing ofchromaffin granule proteins: A profusion of proteases? Neurochem. Int. 22:361-367, 1993.128. O'Connor DT, Kailasam MT, Thal LJ: Cerebrospinal fluid chromogranin A isunchanged in Alzheimer dementia. Neurobiology of Aging 14:267-269, 1993.129. Takiyyuddin MA, DeNicola L, Gabbai FB, Dinh TQ, Kennedy B, Ziegler MG,Sabban EL, Parmer RJ, O'Connor DT: Catecholamine secretory vesicles.Augmented chromogranins and amines in secondary hypertension.Hypertension 21:674-9, 1993.130. MA Testa, RB Anderson, JF Nackley, NK Hollenberg, and the Quality-of-LifeHypertension Study Group. Quality of life and antihypertensive therapy in men:a comparison of captopril with enalapril. New Engl J Med 328:907-13, 1993.131. Simon-Chazottes D, Wu H-J, Parmer RJ, Rozansky DJ, Szpirer J, Kurtz TW,Szpirer C, Guenet J-L, O'Connor DT: Assignment of the chromogranin A locusto homologous regions on mouse chromosome 12 and rat chromosome 6.Genomics 17:252-255, 1993.132. O'Connor DT, Cervenka JH, Stone RA, Parmer RJ, Franco-Bourland R,Madrazo I, Langlais PJ: Chromogranin A immunoreactivity in humancerebrospinal fluid: Properties, relationship to noradrenergic neuronal activity,and variation in neurologic disease. Neuroscience 56:999-1007, 1993.133. Syversen U, Jacobsen MB, Hanssen LE, O'Connor DT, Waldum HL:Chromogranin A and pancreastatin-like immunoreactivity in human carcinoiddisease. European Journal of Gastroenterology & Hepatol 5:1043-1050, 1993.1994134. O'Connor DT, Cervenka JH, Stone RA, Levine GL, Parmer RJ, Franco-BourlandR, Madrazo I, Langlais P, Robertson D, Biaggioni I: Dopamine beta-hydroxylaseimmunoreactivity in human cerebrospinal fluid: properties, relationship to centralnoradrenergic neuronal activity, and variation in Parkinson's disease andcongenital dopamine ß-hydroxylase deficiency. Clinical Science 86:149-158,1994.135. Garcia GE, Gabbai FB, O'Connor DT, Dinh TQ, Kennedy B, Ziegler MG,Takiyyuddin MA: Does chromostatin Influence catecholamine release or bloodpressure in vivo? Peptides 15:195-197, 1994.136. Takiyyuddin MA, Brown MR, Dinh TQ, Cervenka JH, Braun SD, Parmer RJ,Kennedy B, O'Connor DT: Sympatho-adrenal secretion in humans: factorsgoverning catecholamine and storage vesicle peptide co-release. J AutonomPharmacol 14:177-90, 1994.137. Van Kammen DP, Agren H, Yao JK, O'Connor DT, Gurklis JA, Peters JL:Noradrenergic activity and prediction of psychotic relapse following haloperidolwithdrawal in schizophrenia. Am J Psychiatry 151:379-84, 1994.138. Van Kammen DP, Kelley ME, Gilbertson MW, Gurklis J, O'Connor DT. CSFdopamine beta-hydroxylase in schizophrenia: associations with premorbidfunctioning and brain computerized tomography scan measures. American JPsychiatry 15:372-8, 1994.139. Wu HJ, Rozansky DJ, Webster NJG, O'Connor DT. Cell type-specific geneexpression in the neuroendocrine system: A neuroendocrine-specific regulatoryelement in the promoter of chromogranin A, a ubiquitous secretory granule coreprotein. J Clin Invest 94:118-129, 1994.140. Kailasam MT, Lin MC, Cervenka JH, Parmer RJ, Kennedy BP, Ziegler MG,O'Connor DT. Effects of an oral prostaglandin E agonist on blood pressure and18

O'Connor, Daniel T.its determinants in essential hypertension. J of Hum Hypertension 8:515-520,1994.141. Rozansky DJ, Wu HJ, Tang K, Parmer RJ, O'Connor DT. Glucocorticoidactivation of chromogranin A gene expression: identification and characterizationof a novel glucocorticoid response element. J Clin Invest 94:2357-2368, 1994.142. Wu RA, Kailasam MT, Cervenka JH, Parmer RJ, Kennedy BP, Ziegler MG,O'Connor DT. Does lipophilicity of angiotensin converting enzyme inhibitorsselectively influence autonomic neural function in human hypertension? JHypertension 12:1243-1247, 1994.143. Syversen, U; Jacobsen, MB; O’Connor, DT; Ronning, K; Waldum, HL.Immunoassays for measurement of chromogranin A and pancreastatin-likeimmunoreactivity in humans: correspondence in patients with neuroenndocrineneoplasia. Neuropeptides. 26:201-206, 1994.1995144. Cubeddu LX, O'Connor DT, Parmer RJ. Plasma chromogranin A: a marker ofserotonin release and of emesis associated with cisplatin chemotherapy. J ClinOncology 13:681-7, 1995.145. Kailasam MT, Parmer RJ, Stone RA, Shankel S, Kennedy BP, Ziegler MG,O'Connor, DT: Factitious pheochromocytoma: novel mimickry by valsalvamanuever and clues to diagnosis. American Journal of Hypertension 8:651-655,1995.146. Kailasam MT, Parmer RJ, Cervenka JH, Wu RA, Ziegler MG, Kennedy BP,Adegbile IA, O'Connor DT. Divergent effects of dihydropyridine andphenylalkylamine calcium channel antagonist classes on autonomic function inhuman hypertension. Hypertension 26:143-149, 1995.147. Takiyyuddin MA, Parmer RJ, Kailasam MT, Cervenka JH, Kennedy B, ZieglerMG, Lin, M-C, Li J, Grim CE, Wright FA, O'Connor DT. Chromogranin A inhuman hypertension: influence of heredity. Hypertension 26:213-220, 1995.148. Wu HJ, Mahata SK, Mahata M, Webster NJG, Parmer RJ, O'Connor DT. Afunctional cyclic AMP response element plays a crucial role in neuroendocrinecell type-specific expression of the secretory granule protein chromogranin A. JClin Invest 96:568-78, 1995.149. Cubeddu LX, O'Connor DT, Hoffmann L, Parmer RJ. Plasma chromogranin Amarks emesis and serotonin release associated with dacarbazine and nitrogenmustard but not with cyclophosphamide-based chemotherapies. British JCancer 72:1033-8, 1995.1996150. Mahata SK, Kozak CA, Szpirer J, Szpirer C, Modi WS, Gerdes H-H, Huttner WB,O'Connor DT. Dispersion of chromogranin/secretogranin secretory proteinfamily loci in mammalian genomes. Genomics 33:135-139, 1996.151. Brinton TJ, Kailasam MT, Wu RA, Cervenka JH, Chio S-S, Parmer RJ, De MariaAN, O'Connor DT. Arterial compliance by cuff sphygmomanometer: applicationto hypertension, and early changes in subjects at genetic risk. Hypertension28:599-603, 1996.152. Eskeland NL, Zhou A, Dinh TQ, Parmer RJ, Mains RE, O'Connor DT.Chromogranin A processing and secretion: specific role of endogenous andexogenous prohormone convertases in the regulated secretory pathway. J ClinInvest 98:148-156, 1996.153. Mahata MM, Mahata SK, Parmer RJ, O'Connor DT. Vesicular monoaminetransport inhibitors: novel action to inhibit catecholamine release by calciumchannel blockade. Hypertension 28:414-420, 1996.154. Tang K, Wu H, Mahata SK, Taupenot L, Parmer RJ, O'Connor DT. Stimulustranscriptioncoupling in pheochromocytoma cells. Promoter region-specificactivation of chromogranin A biosynthesis. J Biol Chem 271:28382-90, 1996.19

O'Connor, Daniel T.1997155. Parmer RJ, Mahata M, Mahata SK, Sebald MT, O'Connor DT, Miles LA. Tissueplasminogen activator (t-PA) is targeted to the regulated secretory pathway.Catecholamine storage vesicles as a reservoir for the rapid release of t-PA.J Biol Chem 272:1976-1982, 1997.156. Brinton TJ, Cotter B, Kailasam MT, Brown DL, Chio SS, O’Connor DT, andDeMaria AN. Development and Validation of a Noninvasive Method toDetermine Arterial Pressure and Vascular Compliance. Am J Cardiol 80:323-330, 1997.157. Tang K, Wu HJ, Mahata SK, Mahata M, Gill BM, Parmer RJ, and O’Connor DT.Stimulus Coupling to Transcription Versus Secretion in PheochromocytomaCells. Convergent and Divergent Signal Transduction Pathways and the CrucialRoles for Route of Cytosolic Calcium Entry and Protein Kinase C. J Clin Invest100:1180-92, 1997.158. Mahata SK, O’Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM,Parmer RJ. Novel autocrine feedback control of catecholamine release: adiscrete chromogranin A fragment is a non-competitive nicotinic cholinergicantagonist. J Clin Invest 100:1623-33, 1997 (corresponding author).1998159. Toto R, Shultz P, Raij L, Mitchell H, Shaw W, Ramjit D, Toh J, Shahinfar S, forthe Collaborative Group*. Efficacy and Tolerability of Losartan in HypertensivePatients with Renal Impairment. Hypertension. 31:684-691, 1998.160. Taupenot L, Mahata SK, Wu H, and O’Connor DT. Peptidergic Activation ofTranscription and Secretion in Chromaffin Cells: Cis- and Trans- SignalingDeterminants of Pituitary Adenylyl Cyclase Activating Polypeptide (PACAP). JClin Invest 101:863-876, 1998.161. Lacy F, O’Connor DT, and Schmid-Schonbein G. Plasma hydrogen peroxideproduction in hypertensives and normotensive subjects at genetic risk ofhypertension. J Hypertension 16:291-303, 1998.162. Tang K, Wu H, Mahata SK, O'Connor DT. A Crucial Role for the Mitogen-Activated Protein Kinase Pathway in Nicotinic Cholinergic Signaling to SecretoryProtein Transcription in Pheochromocytoma Cells. Molec Pharmacol 54:59-69,1998.163. Dao TT, Kailasam MT, Parmer RJ, Le HV, LeVerge R, Kennedy BP, Ziegler MG,Insel PA, Wright FA, O'Connor DT. Expression of altered alpha-2-adrenergicphenotypic traits in normotensive humans at genetic risk of hereditary (essential)hypertension. J Hypertension 16:779-792, 1998.164. Cubells JF, Van Kammen DP, Kelley ME, Anderson GM, O'Connor DT, PriceLH, Malison R, Rao PA, Kobayashi K, Toshiharu N, Gelernter J. Dopaminebeta-hydroxylase: two polymorphisms in linkage disequilibrium at the structuralgene DBH associate with biochemical phenotypic variation. Hum Genet102:533-540, 1998.165. Kong C, Gill BM, Rahimpour R, Xu L, Feldman RD, Xiao Q, McDonald TJ,Taupenot L, Mahata SK, Singh B, O'Connor DT, Kelvin DJ. Secretoneurin andchemoattractant receptor interactions. J Neuroimmunology 88:91-98, 1998.166. Kailasam, MT, Martinez JA, Cervenka JH, Yen SSC, O'Connor DT, Parmer RJ.Racial differences in renal kallikrein excretion: Effect of the ovulatory cycle.Kidney International 54:1652-1658, 1998.167. Tsigelny I, Mahata SK, Taupenot L, Preece NE, Mahata M, Khan I, Parmer RJ,O'Connor DT. Mechanism of Action of Chromogranin A on Catecholamine20

O'Connor, Daniel T.Release: Molecular Modeling of the Catestatin Region Reveals a Betastrand/Loop/Beta-strandStructure Secured by Hydrophobic Interactions andPredictive of Activity. Regulatory Peptides 77:43-53, 1998.168. M Höcker, R Raychowdhury, T Plath, H Wu, DT O'Connor, B Wiedenmann, SRosewicz, and TC Wang. Sp1 and CREB Mediate Gastrin-dependent Regulationof Chromogranin A Promoter Activity in Gastric Carcinoma Cells. J. Biol. Chem273: 34000-34007, 1998.169. Mahata, M, Mahata, SK, Parmer, RJ, O'Connor, DT. Proadrenomedullin N-terminal 20 peptide: minimal active region to regulate nicotinic receptors.Hypertension 32:907-16, 1998.170. Kennedy, BP, Mahata, SK, O'Connor, DT, Ziegler, MG. Mechanism ofcardiovascular actions of the chromogranin A fragment catestatin in vivo.Peptides 19:1241-8, 1998.1999171. Mahata SK, Mahata M, Wu H, Parmer RJ, O'Connor DT. Neurotrophinactivation of Catecholamine storage vesicle protein gene expression: Signalingto chromogranin A biosynthesis. Neuroscience 88:405-424, 1999.172. Mahata, SK; Mahata, M; Livsey, CV; Gerdes, HH; Huttner, WB; O’Connor, DT.Neuroendocrine cell type-specific and inducible expression of the secretograninII gene: Crucial role of cyclic adenosine monophosphate and serum responseelements. Endocrinology 140:739-749, 1999.173. Subbiah Pugazhenthi, Tracy Boras, Daniel O'Connor, Mary Kay Meintzer, KimA. Heidenreich, and Jane E.-B. Reusch. Insulin-like Growth Factor I-mediatedActivation of the Transcription Factor cAMP Response Element-binding Proteinin PC12 Cells. Involvement Of P38 Mitogen-Activated Protein Kinase-MediatedPathway J. Biol. Chem. 274:2829-2837, 1999.174. Sushil K. Mahata, Manjula Mahata, Robert J. Parmer, and Daniel T. O'Connor.Desensitization Of Catecholamine Release. The Novel Catecholamine Release-Inhibitory Peptide Catestatin (Chromogranin A344-364) Acts At The Receptor ToPrevent Nicotinic Cholinergic Tolerance. J. Biol. Chem. 274:2920-2928, 1999.175. Fred A. Wright, Daniel T. O’Connor, Elizabeth Roberts, Greg Kutey, Charles C.Berry, Lisa U. Yoneda, David Timberlake, Gunther Schlager. Genome Scan forBlood Pressure Loci in Mice. Hypertension 34:625-630, 1999.176. Laurent Taupenot, Manjula Mahata, Sushil Mahata, Daniel T. O’Connor. Time-Dependent Effects of the Neuropeptide PACAP on Catecholamine Secretion.Stimulation and Desensitization. Hypertension 34:1-11, 1999.177. Rainer Büscher, Volker Herrmann, Kevin M. Ring, Mala T. Kailasam, Daniel T.O’Connor, Robert J. Parmer, and Paul Insel. Variability in PhenylephrineResponse and Essential Hypertension: A Search for Human α1B–AdrenergicReceptor Polymorphisms. J Pharmacol Exper Therap 291:793-798, 1999.178. Daniel T. O’Connor, Marwan A. Takiyyuddin, Morton P. Printz, Thai Q. Dinh,Juan A. Barbosa, David J. Rozansky, Sushil K. Mahata, Hongjiang Wu, Brian P.Kennedy, Michael G. Ziegler, Fred A. Wright, Gunther Schlager, Robert J.Parmer. Catecholamine storage vesicle protein expression in genetichypertension. Blood Pressure 8:285-95, 1999.179. WJ Elliott, for the Eprosartan Study Group. Double-blind comparison ofeprosartan and enalapril on cough and blood pressure in unselectedhypertensive patients. Journal of Human Hypertension 13:413-417, 1999.200021

O'Connor, Daniel T.180. CK Song, JA Martinez, MT Kailasam, TT Dao, CM Wong, RJ Parmer, and DTO’Connor. Renal kallikrein excretion: role of ethnicity, gender, environment, andgenetic risk of hypertension. J Human Hypertension 14:461-8, 2000.181. CV Taylor, L Taupenot, SK Mahata, M Mahata, H Wu, Q Jiang, C Caporale, RJParmer, VY Hook, DT O’Connor. Formation of the catecholamine releaseinhibitorypeptide catestatin from chromogranin A: determination of cleavagesites in hormone storage granules. J Biol Chem 275:22905-15, 2000.182. SK Mahata, M Mahata, DT O'Connor. Primary structure and function of thecatecholamine release-inhibitory peptide catestatin (chromogranin A344-364):identification of amino acid residues crucial for activity. Molec Endocrinology14:1525-35, 2000. (cover article)183. V Herrmann, R Buscher, MM Go, KM Ring, JK Hofer, MT Kailasam, DTO'Connor, RJ Parmer, and PA Insel. Beta2-adrenergic receptor polymorphismsat codon 16, cardiovascular phenotypes and essential hypertension inCaucasians and African Americans. American Journal of Hypertension 13:1021-1026, 2000.184. NR Mahapatra, M Mahata, AK Datta, H-H Gerdes, WB Huttner, DT O'Connor,SK Mahata. Neuroendocrine cell type-specific and inducible expression of thechromogranin B gene: crucial role of the proximal promoter. Endocrinology141:3668-78, 2000.185. RJ Parmer, M Mahata, Y Gong, SK Mahata, Q Jiang, DT O'Connor, XP Xi, andLA Miles. Processing of chromogranin A by plasmin provides a novelmechanism for regulating catecholamine secretion. Journal of ClinicalInvestigation 106:907-915, 2000.186. L Taupenot, SK Mahata, M Mahata, RJ Parmer, DT O'Connor. Interaction ofthe catecholamine release-inhibitory peptide catestatin (human chromograninA352-272) with the chromaffin cell surface and Torpedo electroplax: implicationsfor nicotinic cholinergic antagonism. Regulatory Peptides. 95:9-17, 2000.187. MT Kailasam, RJ Parmer, EA Tyrell, RR Henry, and DT O'Connor. CirculatingAmylin In Human Essential Hypertension: Heritability and Early Increase InIndividuals At Genetic Risk. J Hypertension 18:1611-20, 2000.188. F Lacy, MT Kailasam, DT O'Connor, GW Schmid-Schönbein, RJ Parmer.Plasma Hydrogen Peroxide Production in Human Essential Hypertension. Roleof Heredity, Gender, and Ethnicity. Hypertension 36:878-884, 2000.189. F Rao, HR Keiser, DT O'Connor. Malignant Pheochromocytoma: ChromaffinGranule Transmitters and Response to Treatment. Hypertension 36:1045-1052,2000.2001190. DT O’Connor, EA Tyrell, MT Kailasam, LM Miller, JA Martinez, RR Henry, RJParmer, FB Gabbai. Early alteration in glomerular reserve in humans at geneticrisk of essential hypertension: mechanisms and consequences. Hypertension.37:898-906, 2001.191. Agodoa, Lawrence, O’Connor, Daniel, et. al. (African American Study of KidneyDisease and Hypertension [AASK] Study Group; alphabetical authorship). Effectof Ramipril versus Amlodipine on Renal Outcomes in HypertensiveNephrosclerosis: a Randomized, Controlled Trial. J Amer Med Assn 285:2719-2724, 2001.192. Q Jiang, L Taupenot, SK Mahata, M Mahata, DT O’Connor, LA Miles, RJParmer. Proteolytic cleavage of chromogranin A by plasmin. Selective liberation22

O'Connor, Daniel T.of a specific bioactive fragment that regulates catecholamine release. J BiolChem 276:25022-9, 2001.193. M Hocker, T Cramer, DT O’Connor, S Rosewicz, B Wiedenmann, TC Wang.Neuroendocrine-specific and gastrin-dependent expression of a chromogranin A-luciferase fusion gene in transgenic mice. Gastroenterology 121:43-55, 2001.194. J Lewis, L Agodoa, D Cheek, T Greene, J Middleton, D O’Connor, A Ojo, RPhillips, M Sika, J Wright, and the AASK Study Group. Comparison of crosssectionalrenal function measurements in blacks with hypertensivenephrosclerosis and of primary formulas to estimate glomerular filtration rate.American Journal of Kidney Diseases 38:744-53, 2001.2002195. Carlos J. Herrero, Eva Ales, Antonio J. Pintado, Manuela G. Lopez, EstherGarcia-Palomero, Sushil K. Mahata, Daniel T. O’Connor, Antonio G. Garcia,and Carmen Montiel. Modulatory Mechanism of the Endogenous PeptideCatestatin on Neuronal Nicotinic Acetylcholine Receptors and Exocytosis.Journal of Neuroscience 22:377-388, 2002.196. Manjula Mahata, Nitish R. Mahapatra, Daniel T. O'Connor, and Sushil K.Mahata. Chromaffin Cell Catecholamine Secretion: BisindolylmaleimideCompounds Exhibit Novel and Potent Antagonist Effects at the NicotinicCholinergic Receptor in Pheochromocytoma Cells. Molecular Pharmacology61:1340-1347, 2002.197. Daniel T. O’Connor, Mala T. Kailasam, Brian P. Kennedy, Michael G. Ziegler,Noboru Yanaihara, and Robert J. Parmer. Early decline in the catecholaminerelease-inhibitory peptide catestatin in humans at genetic risk of hypertension. JHypertension 20:1-11, 2002.198. Laurent Taupenot, Kimberly L. Harper, Nitish R. Mahapatra, Robert J. Parmer,Sushil K. Mahata, and Daniel T. O’Connor. Identification of a novel sortingdeterminant for the regulated pathway in the secretory protein chromogranin A. JCell Science 115:4827-4841, 2002.199. JW Kusek, P Greene, SR Wang, G Beck, D West, K Jamerson, LY Agodoa, MFaulkner, B Level, for the African American Study of Kidney Disease andHypertension Study Group. Cross-Sectional Study of Health-Related Qualityof Life in African Americans with Chronic Renal Insufficiency: The AfricanAmerican Study of Kidney Diisease and Hypertension Trial. Amer Journal ofKidney Diseases 39:513-524, 2002.200. JT Wright, L Agodoa, G Contreras, T Greene, JG Douglas, J Lash, O Randall, NRogers, MC Smith, S Massry, for the African American Study of KidneyDisease and Hypertension Study Group. Successful Blood Pressure Controlin the African American Study of Kidney Disease and Hypertension. Arch InternalMed 162:1636-1643, 2002.201. JT Wright, G Bakris, T Greene, LY Agodoa, LJ Appel, J Charleston, D Cheek,JG Douglas-Baltimore, J Gassman, R Glassock, L Hebert, K Jamerson, J Lewis,RA Phillips, RD Toto, JP Middleton, SG Rostand, G Contreras, T Greene, JGDouglas, J Lash, O Randall, N Rogers, MC Smith, S Massry, for the AfricanAmerican Study of Kidney Disease and Hypertension Study Group. Effectof Blood Pressure Lowering and Antihypertensive drug Class on Progression ofHypertensive Kidney Disease – Results from the AASK Trial. JAMA 288:2421-2431, 2002.200323

O'Connor, Daniel T.202. Noha H. Farag, Manjula Mahata, Michael G. Ziegler, Daniel T. O'Connor, PaulJ. Mills. Hormone replacement therapy increases renal kallikrein excretion inhealthy postmenopausal women. Life Sciences 72:1279-1288, 2003.203. Laurent Taupenot, Kimberly L. Harper, and Daniel T. O'Connor. Thechromogranin-secretogranin family. New Engl J Med 348:1134-49, 2003.204. Caroline M. Wong, Daniel T. O'Connor, Joseph A. Martinez, Mala T. Kailasam,and Robert J. Parmer. Diminished Renal Kallikrein Responses toMineralocorticoid Stimulation in African-Americans: Determinants of anIntermediate Phenotype for Hypertension. Amer J Hypertension 16:281-289,2003 (corresponding author).205. Surin W. Chitbangonsyn, Payam Mahboubi, Darius Walker, Karin L. Diggle,David S. Timberlake, Robert J. Parmer, and Daniel T. O’Connor. Physicalmapping of autonomic/sympathetic candidate genetic loci for hypertension in thehuman genome: A somatic cell radiation hybrid library approach. J HumanHypertension 17:319-324, 2003.206. Nitish R. Mahapatra, Manjula Mahata, Daniel T. O’Connor, and Sushil K.Mahata. Secretin activation of chromogranin A gene transcription: identificationof signaling pathways in cis and in trans. J Biol Chem 278:19986-94, 2003.207. J Lee, CV Taylor, SP Gaucher, T Toneff, L Taupenot, S Yasothornsrikul, SKMahata, C Sei, RJ Parmer, JM Neveu, WS Lane, BW Gibson, DT O’Connor, VYHook. Primary Sequence Characterization of Catestatin Intermediates andPeptides Defines Proteolytic Cleavage Sites Utilized for ConvertingChromogranin A into Active Catestatin Secreted from NeuroendocrineChromaffin Cells. Biochemistry 42:6938-46, 2003.208. Clifford Wong, Nitish Mahapatra, Surin Chitbangonsyn, Payam Mahboubi,Manjula Mahata, Sushil K. Mahata, and Daniel T. O’Connor. The angiotensin IIreceptor (Agtr1a): Functional regulatory polymorphisms in a locus geneticallylinked to blood pressure variation in the mouse. Physiological Genomics 14:83-93, 2003.209. Sushil K Mahata, Nitish R Mahapatra, Manjula Mahata, Timothy C. Wang, BrianP. Kennedy, Michael G. Ziegler, and Daniel T. O’Connor. Catecholaminesecretory vesicle stimulus-transcription coupling in vivo: demonstration by anovel transgenic promoter/photoprotein reporter, and inhibition of secretion andtranscription by the chromogranin A fragment catestatin. J Biol Chem278:32058-67, 2003.210. Gina M. Schneider, David W. Jacobs, Richard N. Gevirtz, and Daniel T.O'Connor. Cardiovascular hemodynamic response to repeated mental stress innormotensive subjects at genetic risk of hypertension: evidence of enhancedreactivity, blunted adaptation, and delayed recovery. J Human Hypertension17:829-840, 2003.211. Lea JP, Brown DT, Lipkowitz M, Middleton J, Norris K; for the African AmericanStudy of Kidney Disease and Hypertension Study Group. Preventing RenalDysfunction in Patients with Hypertension: Clinical Implications from the EarlyAASK Trial Results. Am J Cardiovasc Drugs. 2003;3(3):193-200.212. Appel LJ, Middleton J, Miller ER 3rd, Lipkowitz M, Norris K, Agodoa LY,Bakris G, Douglas JG, Charleston J, Gassman J, Greene T, Jamerson K, KusekJW, Lewis JA, Phillips RA, Rostand SG, Wright JT. for the African AmericanStudy of Kidney Disease and Hypertension Study Group. The rationale anddesign of the AASK cohort study. J Am Soc Nephrol. 2003 Jul;14(7 Suppl2):S166-72.24

O'Connor, Daniel T.213. Gassman JJ, Greene T, Wright JT Jr, Agodoa L, Bakris G, Beck GJ, Douglas J,Jamerson K, Lewis J, Kutner M, Randall OS, Wang SR. Design and statisticalaspects of the African American Study of Kidney Disease and Hypertension forthe African American Study of Kidney Disease and Hypertension StudyGroup. J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S154-65.2004214. Lewis J, Greene T, Appel L, Contreras G, Douglas J, Lash J, Toto R, VanLente F, Wang X, Wright JT Jr; for the African American Study of KidneyDisease and Hypertension Study Group. A comparison of iothalamate-GFRand serum creatinine-based outcomes: acceleration in the rate of GFR decline inthe African American Study of Kidney Disease and Hypertension. J Am SocNephrol. 2004 Dec;15(12):3175-83.215. Gen Wen, Sushil K. Mahata, Peter E. Cadman, Manjula Mahata, SajalenduGhosh, Nitish R. Mahapatra, Fangwen Rao, Mats Stridsberg, Douglas W. Smith,Payam Mahboubi, Daniel T. O’Connor, and Bruce A. Hamilton. Both rare andcommon polymorphisms contribute functional variation at CHGA, a regulator ofcatecholamine physiology. Amer J Hum Genetics 74:197-207, 2004. (leadarticle)216. Nicholas E. Preece, Minh Nguyen, Manjula Mahata, Sushil K. Mahata, IgorTsigelny, and Daniel T. O’Connor. Conformational preferences of peptidesderived from the catecholamine release-inhibitory (catestatin) region ofchromogranin A. Regulatory Peptides 118:75-87, 2004.217. Ryan S. Fries, Payam Mahboubi, Nitish R. Mahapatra, Sushil K. Mahata,Nicholas J. Schork, Geert W. Schmid-Schoenbein, and Daniel T. O’Connor.Neuroendocrine transcriptome in genetic hypertension: multiple changes indiverse adrenal physiological systems. Hypertension 43:1301-1311, 2004.218. P LeCorre, RJ Parmer, MT Kailasam, BP Kennedy, TP Skaar, H Ho, R Leverge,DW Smith, MG Ziegler, PA Insel, NJ Schork, DA Flockhart, DT O'Connor.Human sympathetic activation by alpha--adrenergic blockade: Bimodal,epistatic influence of cytochrome P450-mediated drug metabolism. ClinPharmacol Therap 139-153, 2004.219. Tiffany A. Greenwood, Peter E. Cadman, Mats Stridsberg, Nicholas J. Schork,and Daniel T. O’Connor. Genome-wide Linkage Analysis of Chromogranin BExpression in the CEPH Pedigrees: Implications for Cardiovascular Physiology.Physiological Genomics 18: 119-127, 2004.220. L Zhang, F Rao, J Wessel, BP Kennedy, BK Rana, L Taupenot, EO Lillie, NJSchork, MG Ziegler, DT O’Connor. Functional allelic heterogeneity andpleiotropy of a repeat polymorphism in the tyrosine hydroxylase locus: Predictionof catecholamine secretion and cardiovascular response to stress in twins.Physiol Genomics 19:277-291, 2004.221. Sushil K. Mahata, Gen Wen, Nitish Mahapatra, Manjula Mahata, Bruce A.Hamilton, and Daniel T. O’Connor. The catecholamine release-inhibitory“catestatin” fragment of chromogranin A: Naturally occurring human variants withdifferent potencies to affect chromaffin cell secretory responses. MolecularPharmacology 66:1180-91, 2004.222. NR Mahapatra, M Mahata, P Hazra, P McDonough, DT O’Connor, SK Mahata.A dynamic cellular pool of calcium in catecholamine storage vesicles: explorationin living cells by a novel vesicle-targeted chromogranin A/aequorin chimericphotoprotein. J Biol Chem 279:51107-21,2004 (co-corresponding author).223. Phillips RA, Faulkner M, Gassman J, Jaen L, Kusek JW, Norris K, Ojo A.25

O'Connor, Daniel T.Recruitment of African Americans with chronic renal insufficiency into amulticenter clinical trial: for the African American Study of Kidney Diseaseand Hypertension Study Group. J Clin Hypertens (Greenwich). 2004Aug;6(8):430-6.224. HA Punzi, C F Punzi, and the Eprosartan Investigation Group. Once-dailyeprosartan mesylate in the treatment of elderly patients with isolated systolichypertension: data from a 13-week double-blind, placebo-controlled, parallel,multicenter study. J Human Hypertension 2004;18(9):655-661.2005225. L Taupenot, KL Harper, DT O’Connor. Role of H + -ATPase-mediatedacidification in sorting and release of the regulated secretory proteinchromogranin A: Evidence for a vesiculogenic function. J Biol Chem 280:3885-3897, 2005.226. H Ho, A Pinto, SD Hall, DA Flockhart, L Li, T Skaar, P Cadman, DT O’Connor,U Wagner, NS Fineberg, MH Weinberger. Association Between CYP3A5Genotype, Blood Pressure and Carbohydrate Intolerance. Hypertension, 45:294-298, 2005.227. RS Friese, P Mahboubi, NR Mahapatra, SK Mahata, NJ Schork, GW Schmid-Schönbein, DT O’Connor. Common genetic mechanisms of blood pressureelevation in two independent rodent models of human essential hypertension.Amer J Hypertension 18:633-52, 2005.228. D King, JP Etzel, S Chopra, J Smith, PE Cadman, F Rao, BK Rana, NJ Schork,PA Insel, DT O’Connor. Human response to lpha2-adrenergic agoniststimulation in an isolated vascular bed in vivo: biphasic influence of dose, age,gender, and receptor genotype. Clin Pharmacol Therap, 77:388-403, 2005.229. Tang CM, Hoerning A, Buscher R, O'Connor DT, Ratjen F, Grasemann H, InselPA. Human adenosine 2B receptor: SNP discovery and evaluation of expressionin patients with cystic fibrosis. Pharmacogenet Genomics. 2005 May;15(5):321-327.230. K Murthy, V Mahboubi, A.Santiago, MT Barragan, R Knoll, HP Schultheiss, DTO’Connor, NJ Schork, and BK Rana. Assessment of Multiple DisplacementAmplification for Polymorphism Discovery and Haplotype Determination at aHighly Polymorphic Locus, MC1R. Human Mutation 26(2), 1-8, 2005.231. Etzel, Jason; Rana, Brinda; Wen, Gen; Parmer, Robert; Schork, Nicholas;O’Connor, Daniel T. Genetic Variation at the Human α2B-Adrenergic ReceptorLocus: Role in Blood Pressure Variation and Yohimbine Response.Hypertension. 2005; 45: 1207-1213.232. Gabriel Contreras, Tom Greene, Lawrence Y. Agodoa, DeAnna Cheek, GeorgeJunco, Donna Dowie, James Lash, Michael Lipkowitz, Edgar R. Miller III, AkinlouOjo, Mohammed Sika, Beth Wilkening, Robert D. Toto; for the AfricanAmerican Study of Kidney Disease and Hypertension (AASK) Study GroupInvestigators. Blood Pressure Control, Drug Therapy, and Kidney Disease.Hypertension, 46:44-50, 2005.233. Daniel T. O'Connor, Peter E. Cadman, Clayton Smiley, Rany Salem, FangwenRao, Joshua Smith, Stephen D. Funk, Sushil K. Mahata, Manjula Mahata, GenWen, Laurent Taupenot, Carmen Gonzalez-Yanes, Kimberly L. Harper, RobertR. Henry, and Victor Sanchez-Margalet. Pancreastatin: Multiple actions onhuman intermediary metabolism in vivo, variation in disease, and naturallyoccurring functional genetic polymorphism. J Clin Endocrinol Metab2005;90(9):5414-25.234. Nitish R. Mahapatra*, Daniel T. O'Connor*, Sucheta Vaingankar*, ManjulaMahata, Eugenie Staite, Hongjiang Wu, Yusu Gu, Amiya P. Sinhahikim , NancyDalton , Brian P. Kennedy, Michael G. Ziegler, John Ross, and Sushil K. Mahata.Targeted ablation of the chromogranin A gene: rescue of the elevated bloodpressure by human homolog. J Clin Invest 115:1942-52, 2005 (co-first author).*235. X Bao, PJ Mills, BK Rana, JE Dimsdale, Nicholas J Schork, DW Smith, F Rao, MMilic, DT O’Connor, MG Ziegler. Interactive Effects of Common Beta-2-Adrenoceptor Haplotypes and Age on Susceptibility to Hypertension andReceptor Function. Hypertension 46:301-7, 2005.236. BP Kennedy, F Rao, T Bottiglieri, S Sharma, EO Lillie, DT O’Connor.Contributions of the sympathetic nervous system, glutathione & body mass to BP26

O'Connor, Daniel T.increases with normal aging: influence of gender. J Hum Hypertension 19:951–969, 2005.2006.237. Nothacker HP, Wang Z, Zeng H, Mahata SK, O'Connor DT, Civelli O.Proadrenomedullin N-terminal peptide and cortistatin activation of MrgX2receptor is based on a common structural motif. Eur J Pharmacol. 2005 Sep5;519(1-2):191-3.238. F Rao, G Wen, S Mahata, B Kennedy, M Stridsberg, K Abel, D Smith, E Eskin, NSchork, B Hamilton, M Ziegler, DT O’Connor. The catecholamine releaseinhibitory peptide catestatin (chromogranin A [CHGA]352-372): A commonnaturally occurring variant (Gly364Ser) causes profound alterations in autonomicactivity in humans. Circulation, acepted, 2006.239. Rany M. Salem, Peter E. Cadman, Gen Wen, Brinda K. Rana, Fangwen Rao, EEskin, Nicholas J. Schork, Mats Stridsberg, Harry J. Ward, Laurent Taupenot,and Daniel T. O’Connor. Polymorphisms at the Chromogranin A and B Loci areRisk Factors for Hypertensive End-stage Renal Disease in African Americans.Submitted (2006).240. NR Mahapatra, M Mahata, SK Mahata, DT O’Connor. The chromogranin Afragment catestatin: specificity, potency, and mechanism to inhibit exocytoticsecretion of multiple catecholamine storage vesicle co-transmitters. JHypertension 24:895-904, 2006.241. Riddle EL, Rana BK, Murthy KK, Rao F, Eskin E, O'Connor DT, Insel PA.Polymorphisms and Haplotypes of the Regulator of G Protein Signaling-2 Genein Normotensives and Hypertensives. Hypertension 47:415-20, 2006.242. TA Greenwood, F Rao, M Stridsberg, NR Mahapatra, M Mahata, EO Lillie, SKMahata, L Taupenot, NJ Schork, DT O’Connor. Pleiotropic effects of noveltrans-acting loci influencing human sympathochromaffin secretion. PhysiolGenomics 25:470-9, 2006.243. J Wessel, G Moratorio, F Rao, M Mahata, L Zhang, W Greene, BK Rana, BPKennedy, S Khandrika, P Huang, EO Lillie, DW Smith, G Wen, BA Hamilton, MGZiegler, JL Witztum, NJ Schork, GW Schmid-Schönbein, DT O’Connor. Creactive protein, an “intermediate phenotype” for inflammation: Human twinstudies reveal heritability, association with blood pressure and the metabolicsyndrome, and the influence of common polymorphism atcatecholaminergic/eta-adrenergic pathway loci. J Hypertension (in press,2006).244. TM Seasholtz, J Wessel, F Rao, BK Rana, S Khandrika, BP Kennedy, EO Lillie,MG Ziegler, DW Smith, NJ Schork, JH Brown, DT O’Connor. Rho kinasePolymorphism Influences Blood Pressure and Systemic Vascular Resistance inHuman Twins: Role of Heredity. Hypertension 47:937-47, 2006.245. F Rao, L Zhang, BP Kennedy, J Wessel, L Taupenot, G Wen, BK Rana, DWSmith, EO Lillie, PE Cadman, RM Salem, NJ Schork, MG Ziegler, DT O’Connor.Tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholaminebiosynthesis: Discovery of common human genetic variants governingtranscription, human autonomic activity and blood pressure in vivo. In revision atCirculation, 2006.246. F Rao, J Wessel, G Wen, L Zhang, BK Rana, BP Kennedy, EO Lillie, RM Salem,BA Hamilton, DW Smith, N-H Holstein-Rathlou, MG Ziegler, NJ Schork, DTO’Connor. Renal albumin excretion, an “intermediate phenotype” fornephropathy: Human twin studies identify influences of heredity, environment, &the interactive role of polymorphism at adrenergic pathway loci. Hypertension(accepted, 2006).247. Valle A, O’Connor DT, Taylor PW, Zhu G, Montgomery GW, Slagboom PE,Martin NG, Whitfield JB: Butyrylcholinesterase:Association with the metabolicsyndrome and identification of two gene loci affecting activity. Clinical Chemistry52:1014-20, 2006.248. BK Rana, PA Insel, S Payne, K Abel, E Beutler, MG Ziegler, NJ Schork, DTO’Connor. Population-Based Sample Reveals Gene-Gender Interactions inBlood Pressure in White Americans. Hypertension 49:96-106, 2007.249. EO Lillie, M Mahata, S Khandrika, F Rao, RA Bundey, G Wen, Y Chen, LTaupenot, DW Smith, SK Mahata, MG Ziegler, M Cockburn, NJ Schork, DTO’Connor. Heredity of endothelin secretion: Human twin studies reveal theinfluence of polymorphism at the chromogranin A locus, a novel determinant ofendothelial function. Accepted at Circulation, 2006.27

O'Connor, Daniel T.250. Mahapatra NR, Mahata M, Ghosh S, Gayen JR, O'Connor DT, Mahata SK.Molecular basis of neuroendocrine cell type-specific expression of thechromogranin B gene: crucial role of the transcription factors CREB, AP-2, Egr-1and Sp1. J Neurochem. 2006;99:119-33.251. C Mosley, L Taupenot, N Biswas, JP Taulane, S Vaingankar, G Wen, NJ Schork,MG Ziegler, SK Mahata, DT O’Connor. Biogenesis of the secretory granule:Chromogranin A (CHGA) coiled-coil structure results in unusual physicalproperties and suggests a mechanism for granule core condensation. Submitted,Biochemistry, 2006.252. DT O’Connor, G Zhu, F Rao, TA Greenwood, M Stridsberg, NG Martin, JBWhitfield. Heritability and genome-wide linkage in US and Australian twinsidentifies novel genomic regions controlling the catecholamine release-inhibitorypeptide catestatin. Submitted.253. L Zhang, F Rao, K Zhang, S Khandrika, M Das, SM Vaingankar, BP Kennedy,BK Rana, DW Smith, J Wessel, RM Salem, JL Rodroguez, SK Mahata, NJSchork, MG Ziegler, DT O’Connor. GTP cyclohydrolase (GCH1), a rate-limitingenzyme in neurotransmitter biosynthesis: Discovery of common human geneticvariants governing nitric oxide, autonomic activity, and cardiovascular risk in twinpairs. Submitted to J Clin Invest.254. Courel M, Rodemer C, Nguyen ST, Pance A, Jackson AP, DT O’Connor, LTaupenot. Secretory granule biogenesis in sympathoadrenal cells: Identificationof a granulogenic determinant in the secretory prohormone chromogranin A. JBiol Chem 2006;281(49):38038-51.255. Gen Wen, Jennifer Wessel, Weidong Zhou, Georg B. Ehret, Fangwen Rao,Mats Stridsberg, Sushil K. Mahata, Peter M. Gent, Madhusudan Das,Richard S. Cooper, Aravinda Chakravarti, Huilin Zhou, Nicholas J. Schork,Daniel T. O’Connor, Bruce A. Hamilton. An ancestral SCG2 variant confersregulation by PHOX2 transcription factors and increased risk of hypertension.Submitted to Curr Biol, 2006.II. Invited articles, book chapters, books.1. O'Connor DT: Angiotensin-converting enzyme inhibition in renal hypertensionwith captopril. In: Cardiovascular Medicine in the '80s: Angiotensin-ConvertingEnzyme Inhibition (JN Cohn, ed.). Biomedical Information Corp., New York,1981. pp 78-83.2. O'Connor DT, Duchin KL: Effect of nadolol on renal hemodynamics in patientswith essential hypertension. In: The Haemodynamics of Nadolol, 2ndInternational Symposium (NK Hollenberg, ed.). Royal Society of Medicinenternational Congress and Symposium Series #51; Academic Press, Inc.(London) and Royal Society of Medicine, 1982. pp 10-16.3. O'Connor DT, Stone RA: The renal kallikrein system: description andrelationship to liver disease. In: The Kidney in Liver Disease (M Epstein, ed.).Elsevier, North Holland, 1983. pp 469-477.4. O'Connor DT, Burton DG, Parmer RJ, Deftos LJ: Human chromogranin A:Detection by immunohistochemistry in C-cells and diverse polypeptide hormoneproducing tumors (Proceedings of the VIII International Conference on CalciumRegulating Hormones, Kobe, Japan, 1983). In: Endocrine Control of Bone andCalcium Metabolism (DV Cohn, T Fujita, JT Potts, RV Talmadge, ed.), ElsevierScience Publishers, BV, 1984. pp 187-190.5. O'Connor DT: Radioimmunoassays of chromogranin. In: Krstulovic A (editor):Quantitative Analysis of Catecholamines and Related Compounds, Chapter 7.Ellis Horwood Ltd., Sussex, England, 1986. pp 302-315.6. O'Connor DT: Review of The Kidney, vols. 1&2 (Brenner BM, and Rector FC,eds.). In: J Amer Med Assoc 256: 2740-1, 1986.7. Parmer RJ, O'Connor DT: Central sympathetic agents in the treatment ofhypertension. In: Contemporary Issues in Nephrology: Pharmacotherapy ofRenal Diseases and Hypertension (WM Bennett, BM Brenner, JH Stein, eds.).Churchill-Livingston, New York, 1987. pp 255-2728

O'Connor, Daniel T.8. O'Connor DT, Deftos LJ: How senstive and specific is measurement of plasmachromogranin A for the diagnosis of neuroendocrine neoplasia? In: Cellular andMolecular Biology of Hormone and Neurotransmitter Containing SecretoryVesicles (RG Johnson, ed.). Ann NY Acad Sci 493: 379-386, 1987.9. O'Connor DT: Review of: The adrenal medulla, volume 4 (by S.W. Carmichael).In: Psychoneuroendocrinology 12:407, 1987.10. Cooper MJ, Helman L, Evans A, Swamy S, O'Connor DT, Helson L:Chromogranin A expression in childhood peripheral neuroectodermal tumors.Advances in Neuroblastoma 2: 175-184, 1988.11. Takiyyuddin MA, Barbosa JA, Hsiao RJ, Parmer RJ, O'Connor DT: Diagnosticvalue of chromogranin A measured in the circulation. In: Markers for Neural andEndocrine Cells (Gratzl M and Langley K, eds.). VCH, New York, 1991. Chapter6, pp. 191-201.12. O'Connor DT, Takiyyuddin MA, Parmer RJ, Cervenka JH, Barbosa JA, HsiaoRJ, Chang YM: Sympathoadrenal catecholamine storage and release in man:insights from the study of chromogranin A. In: Neurobiology andNeuroendocrinology of Stress (Brown MR, Rivier C and Koob G, eds). MarcelDekker, New York, 1991. Chapter 11, pp 217-29.13. Rozansky DJ, O'Connor DT: Review of: Regulatory peptides in paraganglia (byC Heym and W Kummer). In: Psychoneuroendocrinology 14:403, 1989.14. O'Connor DT, Takiyyuddin MA, Cervenka JH, Parmer RJ, Barbosa JA, ChangYM, Hsiao RJ: Circulating chromogranin A as a diagnostic tool in clinicalchemistry. Acta Histochemica, Suppl.-Band XXXVIII, S. 27-33, 1990.15. O'Connor DT: The wise for cure on exercise depend. (editorial) Circulation83:1822-3, 1991.16. Van Kammen DP, Peters JL, O'Connor DT, Gelernter J, Ekman R, Widerlov E,Guidotti A, Perel J, Kelley ME, Beuger M, Gurklis J: CSF peptides and long termneuroleptic treatment in schizophrenia: effects of haloperidol withdrawal andrelapse. In: Biological Psychiatry, Volume 1 (G. Racagni et al, eds.). ElsevierScience Publishers B.V., 1991. pp. 580-2.17. Kailasam MT, O'Connor DT, Parmer, RJ: The regulation and role ofcatecholamines in hypertension and pheochromocytoma. Current Opinion inEndocrinology and Diabetes 1:135-142, 1994.18. O'Connor DT, Wu HJ, Gill BM, Rozansky DJ, Tang K, Mahata SK, Mahata M,Eskeland NL, Videen JS, Zhang X, Takiyyuddin MA, Parmer RJ: Hormonestorage vesicle proteins: Transcriptional basis of the widespread neuroendocrineexpression of chromogranin A, and evidence of its diverse biological actions,intracellular and extracellular. Ann NY Acad Sci 733:36-45, 1994.19. Martinez JA, O'Connor DT: Somatic cell gene therapy for a trait as complex ashypertension? (editorial). J Clin Invest 95:1426, 1995.20. Kailasam MT, O'Connor DT, Parmer RJ. Hereditary intermediate phenotypes inAfrican American hypertension. Ethnicity and Health 1(2),133-144, 1996.21. O'Connor DT: Adrenal medulla, catecholamines and pheochromocytoma. In:Cecil Textbook of Medicine published by W.B. Saunders. Editors: JC Bennett, FPlum. 20th edition, Chapter 204.2, pp. 1253-1257, 1996.22. O'Connor DT, Kailasam MT, Parmer RJ. Complex Trait Genetics: New MethodsYield a Result for Essential Hypertension. (editorial) In: J Clin Invest, 97(9),1997-98, 1996.23. Mahata SK, Mahata M, Yoo SH, Taupenot L, Wu HJ, Aroda V, Livsey CV,Taulane JP, Goodman M, Parmer RJ, O'Connor DT: A Novel, CatecholamineRelease-InhibitoryPeptide from Chromogranin A: Autocrine Control of Nicotinic Cholinergic-Stimulated Exocytosis. Advances in Pharmacology 42:206-4, 1998.24. Kunau RT, Nasca TJ, Braun WE, Bushinsky DA, Faber MD, Hebert LA, Hou SH,Mehta R, O'Connor DT, Paller MS, Stivelman JC, Torres VE, Toto RD. 1998.Nephrology and Hypertension MKSAP (Medical Knowledge Self-Assessment29

O'Connor, Daniel T.Program), Second Edition, published by American College ofPhysicians/American Society of Internal Medicine.25. L Taupenot, SK Mahata, H Wu, K Tang, M Mahata, RJ Parmer, DT O’Connor.Peptidergic stimulus-transcription coupling in chromaffin cells: regulation ofchromogranin A gene expression by the neurotransmitter pituitary adenylylcyclase-activating polypeptide (PACAP). Pp 249-259, in: The Adrenal ChromaffinCell. Eds: T Kanno, Y Nakazato, K Kumakura. Hokkaido University Press,Sapporo, Japan, 1998, 394 pages.26. O’Connor, Daniel T. Chromaffin cell mechanisms: understandingcatecholamine storage and release. Trends in Pharmacolgical Sciences 20:431-432, 1999.27. DT O’Connor, PA Insel, MG Ziegler, VY Hook, DW Smith, BA Hamilton, PWTaylor, RJ Parmer. Heredity and the Autonomic Nervous System in HumanHypertension. Current Hypertension Reports 2:16-22, 2000.28. L Taupenot, Manjula Mahata, Sushil K. Mahata, Hongjiang Wu, and Daniel T.O'Connor. Regulation of Chromogranin A Transcription and CatecholamineSecretion by the Neuropeptide PACAP: Stimulation and Desensitization.Advances in Experimental Medicine and Biology, Vol 482, Chromogranins:Functional and Clinical Aspects, Chapter 7, pp 97-111, 2000.29. Robert J. Parmer, Sushil K. Mahata, Qijiao Jiang, Laurent Taupenot, Yun Gong,Manjula Mahata, Daniel T. O'Connor, and Lindsey A. Miles. TissuePlasminogen Activator and Chromaffin Cell Function. Advances in ExperimentalMedicine and Biology, Vol 482, Chromogranins: Functional and Clinical Aspects,Chapter 14, pp 179-192, 2000.30. Sushil K. Mahata, Manjula Mahata, Carolyn V. Livsey Taylor, Laurent Taupenot,Robert J. Parmer, and Daniel T. O'Connor. The Novel Catecholamine ReleaseInhibitory Peptide Catestatin (Chromogranin A344-364): Properties and Function.Advances in Experimental Medicine and Biology, Vol 482, Chromogranins:Functional and Clinical Aspects, Chapter 21, pp 263-277, 2000.31. Daniel T. O'Connor, Sushil K. Mahata, Laurent Taupenot, Manjula Mahata,Carolyn V. Livsey Taylor, Mala T. Kailasam, Michael G. Ziegler, and Robert J.Parmer. Chromogranin A in Human Disease. Advances in ExperimentalMedicine and Biology, Vol 482, Chromogranins: Functional and Clinical Aspects,Chapter 31, pp 377-388, 2000.32. Timberlake, DS; O'Connor, DT; Parmer, RJ. Molecular genetics of essentialhypertension: recent results and emerging strategies. Current Opinion inNephrology and Hypertension 10(N1):71-79, 2001.33. L Taupenot, DT O’Connor. Chromogranins/Secretogranins. In: WileyEncyclopedia of Molecular Medicine, Vol 5, pp 772-779, 2002.34. Daniel T. O’Connor, Lee E. Eiden (editors). The Chromaffin Cell: TransmitterBiosynthesis, Storage, Release, Actions, And Informatics. Ann NY Acad Sci,Volume 971:xv-659, 2002.35. Daniel T. O’Connor. Preface. The Chromaffin Cell: Transmitter Biosynthesis,Storage, Release, Actions, And Informatics. In: The Chromaffin Cell: TransmitterBiosynthesis, Storage, Release, Actions, And Informatics. Eds: Daniel T.O’Connor and Lee E. Eiden. Ann NY Acad Sci 971:xv-xvi, 2002.36. Sushil K. Mahata, Nitish R. Mahapatra, Manjula Mahata, Daniel T. O’Connor.Neuroendocrine cell type-specific and inducible expression ofchromogranin/secretogranin genes: crucial promoter motifs. In: The ChromaffinCell: Transmitter Biosynthesis, Storage, Release, Actions, And Informatics. Eds:Daniel T. O’Connor and Lee E. Eiden. Ann NY Acad Sci 971:27-38, 2002.37. Xuping Bao, Brian Kennedy, Robert Enns, Manjula Mahata, Sushil Mahata,Daniel O’Connor, Michael G. Ziegler. A Truncated Mouse Phenylethanolamine30

O'Connor, Daniel T.N-methyltransferase Splice Variant with Dominant Negative Activity. In: TheChromaffin Cell: Transmitter Biosynthesis, Storage, Release, Actions, AndInformatics. Eds: Daniel T. O’Connor and Lee E. Eiden. Ann NY Acad Sci971:89-91, 2002.38. Laurent Taupenot, Kimberly L. Harper, Nitish R. Mahapatra, Robert J. Parmerand Daniel T. O'Connor. Intracellular protein trafficking into catecholaminestorage vesicles: novel chimeric photoproteins visualized by deconvolutionfluorescence microscopy. In: The Chromaffin Cell: Transmitter Biosynthesis,Storage, Release, Actions, And Informatics. Eds: Daniel T. O’Connor and Lee E.Eiden. Ann NY Acad Sci 971:262-5, 2002.39. Peter E. Cadman, Fangwen Rao, Sushil K. Mahata, and Daniel T. O’Connor.Studies of the Dysglycemic Peptide Pancreastatin Using a Human ForearmModel. In: The Chromaffin Cell: Transmitter Biosynthesis, Storage, Release,Actions, And Informatics. Eds: Daniel T. O’Connor and Lee E. Eiden. Ann NYAcad Sci 971:528-9, 2002.40. Fangwen Rao, Harry R. Keiser, and Daniel T. O'Connor. Malignant and benignpheochromocytoma: chromaffin granule transmitters and the response tomedical and surgical treatment. In: The Chromaffin Cell: TransmitterBiosynthesis, Storage, Release, Actions, And Informatics. Eds: Daniel T.O’Connor and Lee E. Eiden. Ann NY Acad Sci 971:530-2, 2002.41. Daniel T. O’Connor, Mala T. Kailasam, Brian P. Kennedy, Michael G. Ziegler,Noboru Yanaihara, and Robert J. Parmer. The catecholamine release-inhibitory“catestatin” region of chromogranin A: early decline in humans at genetic risk ofhypertension. In: The Chromaffin Cell: Transmitter Biosynthesis, Storage,Release, Actions, And Informatics. Eds: Daniel T. O’Connor and Lee E. Eiden.Ann NY Acad Sci 971:533-5, 2002.42. PE Cadman, DT O’Connor. Pharmacogenomics of hypertension. Curr OpinNephrol Hypertension 12:61-70, 2003.43. Math P. Cuajungco, Yukio Ando, Felicia B. Axelrod, Italo Biaggioni, DavidGoldstein, Alan E. Guttmacher, Katrina Gwinn-Hardy, Maureen K. Hahn, Max J.Hilz, Giris Jacob, Jordan Jens, William R. Kennedy, Stephen B. Liggett, DanielT. O’Connor, Sonia R. Peltzer, David Robertson, Beresh Y. Rubin, QuandraScudder, Linda J. Smith, Gail E. Sonenshein, Jesper Q. Svejstrup, Yang Xu andSusan A. Slaugenhaupt. Hereditary Dysautonomias: Current Knowledge andCollaborations for the Future. Clin Autonom Research. 13:180-95, 2003.44. O'Connor DT: Adrenal medulla, catecholamines and pheochromocytoma.Chapter 241 (pp 1419-1424), in: Cecil Textbook of Medicine, published by W.B.Saunders, Philadelphia. Editors: L Goldman and D Ausiello. 22nd edition, 2004.45. C Smiley, S Chopra, DT O’Connor. Hypertension genetics: candidate geneticloci, “intermediate” phenotypes, and genome-wide searches for susceptibilityloci. In: The Year In Hypertension, Chapter 7, pp153-172, 2004 (Nova).46. RS Fries, F Rao, DT O’Connor. The adrenal medulla in hypertension. In:Molecular Mechanisms of Hypertension. JR Sowers, editor. Taylor and Francis,London, UK. Chapter 24, Pgs 1-8, 2006.47. F Rao, R Friese, G Wen, L Zhang, L Taupenot, SK Mahata, MG Ziegler, DTO’Connor. Catecholamines, pheochromocytoma, and hypertension: genomicinsights. In press, Comprehensive Hypertension, Elsevier, 2006 (Ed: E.Schiffrin).48. K Zhang, F Rao, G Wen, L Taupenot, SK Mahata, DT O’Connor.Catecholamine storage vesicles and the metabolic syndrome: The role of the31

O'Connor, Daniel T.chromogranin A fragment pancreastatin. Diabetes, Obesity and Metabolism8:621-633, 2006.49. EO Lillie, DT O’Connor. Early phenotypic changes in hypertension: A role for theautonomic nervous system and heredity. Hypertension 2006;47:331-333.III. Published abstracts.19781. O'Connor DT, Eurman G, Frigon RP, Stone RA: Antihypertensive mechanismsof chronic diuretic and propranolol therapy. Kidney Int 12: 471, 1978.Presented, ASN, 1977.2. Preston RA, O'Connor DT, Mitas JA II, Stone RA: Effect of propranolol onbaroreflex arc function in essential hypertension. Clin Res 26: 101A, 294A,1978. Presented, AFCR, 1978.3. O'Connor DT, Preston RA, Eurman G, Frigon RP, Stone RA: Involvement ofthe kallikrein-kinin system in the antihypertensive response to diuretic andpropranolol therapy. Clin Res 26: 101A, 293A, 1978. Presented, AFCR, 1978.4. Preston RA, O'Connor DT, Mitas JA II, Stone RA: Effects of chronic clonidinetherapy on baroreflex sensitivity in essential hypertension. Clin Res 26: 293A,1978; Kidney Int 14: 693, 1978.5. Preston RA, O'Connor DT, Mitas JA II, Stone RA: Proposed mechanism ofaction of prazosin: effect on renal hemodynamics. Clin Res 26: 294A, 1978,Kidney Int 14: 774, 1978.6. O'Connor DT, Preston RA, Stone RA: Thiazide induced increase in salt andwater appetite is mediated by the renin angiotensin system, not by volume orosmolality. Kidney Int 14: 744, 1978.7. O'Connor DT, Stone RA, Preston RA, Mitas JA, Wall J: Racial variation in theantihypertensive response to prazosin hydrochloride. Kidney Int 14: 657, 1978.8. O'Connor DT, Preston RA, Stone RA: Thiazides diminish renal vascularresistance in essential hypertensive man. Kidney Int 14: 700, 1978, Clin Res 27:17A, 316A, 1979. Presented, AFCR, 1979.9. O'Connor DT, Grundy SM, Preston RA, Mitas JA II, Stone RA: Thiazidesincrease plasma cholesterol in essential hypertension. Kidney Int 14: 657, 1978;Clin Res 27: 48A, 1979.10. O'Connor DT, Preston RA, Stone RA: Serum chloride as a determinant ofthiazide induced increase in plasma renin activity. Kidney Int 14: 700, 1978.11. Preston RA, O'Connor DT, Stone RA: Propranolol induced renalvasoconstriction: diminished renal perfusion and glomerular filtration. Kidney Int14: 77, 1978; Clin Res 27: 17A, 469A, 1979. Presented, ASN, 1978.12. Olshan A, O'Connor DT, Frigon RP, Stone RA: Furosemide antihypertensiveeffects are associated with the kallikrein-kinin system. Kidney Int 14: 701, 1978;Clin Res 27: 63A, 1979. Presented, AFCR, 1979.13. Cohen IM, O'Connor DT, Preston RA, Frigon RP, Stone RA: Alteration ofintrarenal hemodynamics during chronic sympatholytic therapy. Kidney Int 14:754, 1978.14. Cohen IM, O'Connor DT, Preston RA, Stone RA: Failure of chronic clonidinetherapy to alter indices of sympathetic nervous system activity. Kidney Int 14:648, 1978.197915. Preston RA, O'Connor DT, Wall J, Stone RA: Vasodilator therapy and the renalcirculation: diminished afferent arteriolar resistance following prazosin therapy.Clin Res 27: 17A, 1979.16. Cohen IM, Mitas JA, O'Connor DT, Preston RA, Stone RA: Antihypertensivemechanism of chronic clonidine therapy. Clin Res 27: 15A, 1979; Clin Res 27:312A, 1979.32

O'Connor, Daniel T.17. Cohen IM, O'Connor DT, Preston RA, Frigon RP, Stone RA: Effect of clonidineon intrarenal hemodynamics. Clin Res 27: 60A, 1979.18. Cohen IM, O'Connor DT, Stone RA: Antihypertensive superiority of guanabenzhydrochlorothiazidecombination over hydrochlorothiazide alone. Clin Res 27:230A, 1979.19. Barg A, O'Connor DT, Cervenka J, Sanfelippo M, Henderson L: Control ofhypertension with hemofiltration. Kidney Int 16: 779, 1979; Clin Res 28: 61A,1980.20. Cohen IM, O'Connor DT, Skowsky R, Stone RA: Arginine vasopressin inessential hypertension: effects of prazosin therapy. Kidney Int 16: 904, 1979;Clin Res 28: 38A, 1980. Presented, AFCR, 1980.21. Cohen IM, O'Connor DT, Skowsky R, Stone RA: The role of argininevasopressin in essential hypertension. Kidney Int 16: 904, 1979.22. Olshan AR, O'Connor DT, Cohen IM, Stone RA: An analysis of hypertension inadult onset diabetics. Kidney Int 16: 907, 1979.23. O'Connor DT, Sasso E, Preston RA, Stone RA: Prazosin decreases baroreflexsensitivity in man. Kidney Int 16: 907, 1979; Clin Res 28: 38A, 1980.24. Warren SE, Cohen IM, O'Connor DT, Cervenka J, Stone RA: Racial differencesin response to guanabenz and hydrochlorothiazide. Kidney Int 16: 909, 1979;Clin Res 28: 19A, 1980.25. Warren SE, Cohen IM, O'Connor DT, Cervenka J, Stone RA: Heterogeneity ofrenal hemodynamic response to captopril. Kidney Int 16: 909, 1979; Clin Res28: 65A, 1980, Presented, AFCR, 1979.26. Olshan AR, O'Connor DT, Cohen IM, Stone RA: Baroreflex dysfunction in adultonset diabetics with hypertension. Kidney Int 16: 922, 1979.27. Warren SE, Cohen IM, O'Connor DT, Cervenka J, Stone RA: Mechanism ofaction of hydrochlorothiazide and guanabenz. Kidney Int 16: 924, 1979; ClinRes 28: 19A, 1980.28. Mitas JA, Hedges JC, Peterson NR, O'Connor DT, Wilus PJ: Use of elevatedurinary kallikrein excretion as a marker for nephrocarcinoma. Kidney Int 16: 934,1979.198029. Hsueh WA, Carlson EJ, O'Connor DT, Warren SE: Evidence that a structuralalteration of renin is required for its activation by kallikrein. Clin Res 28: 331A,1980.30. O'Connor DT, Barg AP, Cervenka J: Propranolol effects on sodium and volumehomeostasis in essential hypertension: enhanced fractional sodium excretiondespite diminished glomerular filtration rate and urinary kallikrein excretion. ClinRes 28: 355A, 1980.31. Warren SE, O'Connor DT, Stone RA: Mechanism of blood pressure reductionduring sodium restriction in hypertensive man. Clin Res 28: 337A, 1980.32. Warren SE, O'Connor DT, Stone RA: Sympathetic nervous activity duringdietary sodium depletion in hypertension. Clin Res 28: 337A, 1980.33. Warren SE, O'Connor DT, Cohen IM, Cervenka J: Captopril alters autonomicfunction in hypertensive man. Circ 62(Suppl. III): III89, 1980; Clin Res 29: 24A,1981; Presented, AFCR, 1981.198134. Zager PG, Hsueh WA, Leutscher JA, O'Connor DT, Warren SE: Defect inconversion of inactive renin to active renin in diabetic subjects with nephropathyand hyperkalemia. Kidney Int 19:178, 1981.35. Warren SE, O'Connor DT, Cervenka J: Racial differences during chronicprazosin therapy of hypertension. Kidney Int 19: 177, 1981.36. Warren SE, O'Connor DT, Levine GL: Dopamine-beta-hydroxylasemeasurements and myocardial function. Kidney Int 19: 177, 1981.37. Barg A, Vincente F, Amend W, O'Connor DT: Urinary kallikrein after renaltransplantation: findings in hypertensive versus normotensive graft recipients;33

O'Connor, Daniel T.living related donor vs. cadaveric grafts; and acute rejection vs. acute tubularnecrosis. Kidney Int 19: 163, 1981; Clin Res 29: 71A, 1981.38. O'Connor DT, Frigon RP: Human chromogranin A: the major catecholaminestorage vesicle protein. Clin Res 29: 44A, 359A, 1981; Presented, AFCR, 1981.39. Griswold WR, Brams M, O'Connor DT, Reznick V, Mendoza SA: Captopriltherapy in severe childhood hypertension. Clin Res 29: 121A, 1981.40. Sokoloff RL, O'Connor DT, Frigon RP: Chromogranins A, B, and C of the cowand human: comparisons. Fed Proc 40: 1842, 1981; Presented, Am Soc BiolChem, 1981.41. Foote SL, Morrison JH, Bloom FE, O'Connor DT: Laminar and regionaldistribution of norepinephrine fibers in squirrel monkey neocortex as revealed byimmunohistochemistry. Soc Neuro Abstr 7: 792, 1981.198242. O'Connor DT, Mosely C, Cervenka J, Taylor A, Slutsky R: Guanabenzselectively reduces renal vascular resistance in essential hypertension. KidneyInt 21:191, 1982; Presented, ASN, 1981.43. Henderson LW, Barg AP, Sanfelippo ML, O'Connor DT: Changes ofprecapillary resistance with hemofiltration in the maintenance dialysis patient withhypertension. Kidney Int 21: 188, 1982.44. O'Connor DT, Shoemaker W, Frigon RP, Azad R, Bloom F: Enkephalins inhuman pheochromocytoma: localization with catecholamines in catecholaminestorage vesicles. Clin Res 30: 50A, 338A, 1982. Presented AFCR, 1982.45. O'Connor DT, Gochman N: Lactate dehydrogenase activity in humanpheochromocytoma: serum elevation, isoenzyme pattern and tissue source. ClinRes 30: 50A, 1982.46. O'Connor DT, Frigon RP: A radioimmunoassay for bovine chromogranin A.Clin Res 30(2): 338A, 1982.47. Duchin KL, O'Connor DT, Barg AP: Chronic effects of oral nadolol on renalhemodynamics in essential hypertension. J Clin Pharmacol 22(4) (suppl.): 6A,1982.48. Gozes I, O'Connor DT, Bloom FE: Sequestering of vasoactive intestinalpolypeptide in pheochromocytoma chromaffin granules: a possible highmolecular weight precursor. Soc Neurosci Abstr 8: 1982.198349. O'Connor DT, Frigon RP: Enkephalins in human pheochromocytoma:subcellular storage in and release from catecholamine storage vesicles andgeneration from precursors by controlled proteolysis. Kidney Int 23: 174, 1983;Presented, ASN, 1982.50. Bernstein KN, Barg AP, Cervenka J, O'Connor DT: Sympatholytic effect of anon-CNS penetrating beta blocker in hypertension is unmasked byparasympathetic inhibition. Kidney Int 23: 167, 1983; Presented, ASN, 1982.51. O'Connor DT: Chromogranin A: the major soluble protein of adrenal medullarycatecholamine storage vesicles: Ubiquitous occurrence in polypeptide hormoneproducing tissues derived from neural crest. Clin Res 31: 25A, 275A, 1983; FedProc 42: 381, 1983; Presented, AFCR, 1983.52. O'Connor DT, Levine GL, Frigon RP: Elevated cerebrospinal fluid dopaminebeta-hydroxylaseby radioimmunoassay in human hypertension. Clin Res 31:42A, 333A, 1983; Presented, AFCR, 1983.53. Parmer R, Mosley C, O'Connor DT: Enkephalins in pheochromocytoma:Studies in a rat model. Clin Res 31(2): 333A, 1983; Presented, AFCR, 1983.54. Bernstein KN, Mosley C, O'Connor DT, Cervenka J: Enalapril (MK-421) anangiotensin converting enzyme inhibitor: effects on sympathetic nervous systemfunction during treatment of hypertension. Clin Res 31(2): 246A, 1983.55. Snavely MD, Mahan LC, O'Connor DT, Insel PA: Adrenergic receptor subtypesare selectively down regulated in pheochromocytoma. Clin Res 31(2): 254A,1983.34

O'Connor, Daniel T.198456. O'Connor DT, Klein RL: Chromogranin A: presence in large dense corecatecholamine storage vesicles of sympathetic nerve. Clin Res 32(2): 336A,1984; Presented, AFCR, 1984.57. O'Connor DT, Burton DG, Deftos L: Chromogranin A, the major catecholaminestorage vesicle soluble protein: immunohistology reveals a widespreadoccurrence in normal polypeptide hormone producing tissues. Kidney Int 25(1):204, 1984; Presented, ASN, 1984.58. O'Connor DT: Human plasma chromogranin A: Detected by radioimmunoassayand elevation in pheochromocytoma and in essential hypertension. Clin Res32(2): 336A, 1984; Presented, AFCR, 1984.59. O'Connor DT, Deftos LJ: Human chromogranin A: Radioimmunoassaydemonstrates diagnostic plasma elevations in diverse peptide producing tumors.Clin Res 32(2): 547A, 1984; Presented, AFCR, 1984.198560. O'Connor DT, Sokoloff RL: Dopamine-beta-hydroxylase: is there a structuraldifference between soluble and membrane-bound DBH forms in catecholaminestorage vesicles of bovine adrenal medulla or human pheochromocytoma? ClinRes 33(2): 367A, 1985; Presented, AFCR, 1985.61. Mezger MS, O'Connor DT: Electrostatic interaction between Ca 2+ and adrenalcatecholamine storage vesicle soluble proteins (chromogranins). Clin Res 33(2):365A, 1985; Presented, AFCR, 1985.198662. Mezger MS, O'Connor DT: Plasma chromogranin A in subjects with renalfailure: elevation proportional to degree of renal failure and retention ofimmunoreactive fragments. Kidney Int 29(1): 198, 1986.63. Parmer RJ, O'Connor DT: Renal hemodynamic stability after convertingenzyme inhibition in renovascular hypertension. Kidney Int 29(1): 255, 1986;Presented, ASN, 1985.64. O'Connor DT, Deftos LJ: How sensitive and specific is measurement of plasmachromogranin A in diagnosis of neuroendocrine neoplasia? Clin Res 34: 551A,1986; Presented, AFCR, 1986.198765. O'Connor DT, Pandian MR, Cervenka J, Mezger M, Parmer RJ: What is thesource and disposition of chromogranin A in normal human plasma? Clin Res35: 605A, 1987; Presented, AFCR, 1987.66. Parmer RJ, O'Connor DT: Sympathetic nervous system activity in hypertension:Are there racial differences? Kidney Int 30: 306, 1987; Presented, ASN, 1986.67. O'Connor DT, Mezger M, Chang Y-M: Catecholamines interact withchromogranins, the major catecholamine storage vesicle soluble core proteins.Kidney Int 30: 305, 1987; Presented, ASN, 1986.198868. O'Connor DT, Subramani S: Do transcriptional enhancers also augment DNAreplication? Clin Res 36(1): 184A, 1988; Presented, AFCR, 1988.69. O'Connor DT, Takiyyuddin M: Synthetic peptide epitopes: clues to the structure,conformation, distribution and processing of chromogranin A (CgA). Clin Res36(1): 187A, 1988; Am J Htn 1:52A, 1988. Presented, ASH, 1988.70. Takiyyuddin M, Cervenka J, Kennedy B, Stuenkel C, O'Connor DT: Pulsatilerelease of plasma chromogranin A in man. Am J Hypertension 1:43A, 1988.Presented, ASH, 1988.35

O'Connor, Daniel T.71. Parmer RJ, Koop AJ, Handa M, O'Connor DT: Molecular cloning ofchromogranin A from a rat pheochromocytoma cDNA library provides insight intofunctional domains. Am J Htn 1:65A, 1988. Presented, ASH, 1988.72. Takiyyuddin M, Cervenka J, Pandian MR, O'Connor DT: Selective adrenalmedullary stimulation releases chromogranin A in man. Am J Htn 1: 52A, 1988.Presented, ASH, 1988.73. Wu HJ, Parmer RJ, Koop AH, O'Connor DT: Molecular cloning of a dopaminebeta-hydroxylasecDNA. Am J Htn 1: 65A, 1988. Presented, ASH, 1988.198974. Takiyyuddin M, Sullivan P, Cervenka J, O'Connor DT: Exocytotic catecholamineand chromogranin A (CgA) corelease during selective stimulation of thesympathetic nervous system (SNS) in man. Presented, Am Soc Nephrol, 1988.Kidney Int 35:335, 1989.75. O'Connor DT, Neumann HPH: Chromogranin A (CgA) disposition anddistribution in man: Insights from CgA kinetics after resection ofpheochromocytoma (pheo). Presented, Am Soc Nephrol, 1988. Kidney Int 35:333, 1989.76. Wu HJ, Parmer RJ, Koop AH, Rozansky DJ, O'Connor DT. Dopamine-betahydroxylase(DBH): a cDNA clone illuminates structural domains. Presented,ASCB/ASBMB, 1988-9. Abstracts p. 507a, 1989.77. O'Connor DT, Cervenka JH, Parmer RJ. Chromogranin A (CgA): Specificdetection in human cerebrospinal fluid (CSF). Clin Res 37(1): 162A, 1989.78. Hsiao RJ, Neumann HPH, Takiyyuddin MA, O'Connor DT. Chromogranin A(CgA) in familial pheochromocytoma (pheo): Diagnostic screening value,prediction of tumor mass, and post-resection kinetics indicating twocompartmentdistribution. Clin Res 37(1): 156A, 1989. Presented, WSCI, 1989.79. Peirce J, Gill B, DeGuire M, Dinh T, Garrod S, O'Connor DT: Secretory vesicleprocessing of chromogranin A (CgA). Presented to FASEB annual meeting,1989.80. Takiyyuddin MA, Cervenka J, Baron AD, O'Connor DT: Somatostatin (SRIF)suppresses the pulsatile release of chromogranin A (CgA) in man. Presented,AFCR National Meeting, 1989. Clin Res 37(2): 461A, 1989.81. Takiyyuddin MA, Sullivan P, Cervenka J, Brown M, O'Connor DT: Postexerciseincrease in plasma neuropeptide-Y (NPY) and norepinephrine (NE). Presented,AFCR National Meeting, 1989. Clin Res 37(2): 301A, 1989.82. Hsiao RJ, Seeger RC, O'Connor DT: Chromogranin A (CgA) in children withneuroblastoma (NB): Plasma concentration parallels disease stage and predictssurvival. Presented, AFCR National Meeting, 1989. Clin Res 37(2): 576A, 1989.83. Polikar R, Kennedy B, Ziegler M, O'Connor DT, Smith J, Maisel A, Nicod P:Norepinephrine plasma kinetics in hypothyroid patients before and followingreplacement therapy. Presented, ASCI National Meeting, 1989. Clin Res 37(2):362A, 1989.84. Carmichael SW, Tyce GM, Yaksh TL, O'Connor DT, Stoddard SL: Secretion ofcatecholamines, neuropeptide Y, and chromogranin A from the adrenal medullavia venous and lymphatic routes. 12th Meeting Int Soc for Neurochemistry,Algarve, Portugal, 1989. J Neurochem 52:S87, 1989.85. Barbosa JA, Gill BM, Hsiao RJ, Garrod S, O'Connor DT: Human chromograninA: synthetic peptide reagents, preparative electrophoresis, and microsequencingdemonstrate multiple post-translational modifications. Presented, ASN, 1989.Kidney International 37: 382, 1990.86. Takiyyuddin MA, Barbosa JA, Casto RL, Printz MP, O'Connor DT: Augmentedstorage and release of a catecholamine storage vesicle protein in genetichypertension. Presented, ASN, 1989. Kidney International 37: 394, 1990.87. Parmer RJ, Wood PJ, O'Connell N, O'Connor DT: Chromogranin A in theevaluation of hypercalcemia. Submitted, ASN, 1989. Kidney International 37:469, 1990.36

O'Connor, Daniel T.88. O'Connor DT, Takiyyuddin MA, Parmer RJ, Hsiao RJ, Cervenka JH, Gill BM,Barbosa JA: Chromogranin A and the adrenal medulla in hypertension.Presented, 5th International Symposium on Chromaffin Cell Biology, Jerusalem,Israel, May 1989. Abstracts, page 58. Presented (plenary lecture), ASH, 1989.199089. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O'Connor DT: Chromogranin A: Can itidentify pheochromocytoma in human hypertensive populations? Presented,WSCI, Carmel, CA, February 1990. Clin Res 38: 151A, 1990.90. Parmer RJ, Stone RA, Cervenka JH, O'Connor DT: Baroreflex sensitivity inhuman hypertension is genetically determined. Presented ASCI, 1990.Presented, International Society of Hypertension, Montreal, 1990. Presented,ASN, 1990. Clin Res 38(2): 476A, 1990. J Am Soc Nephrol 1(4):510, 1991.91. Takiyyuddin MA, Cervenka JH, Barbosa JA, Parmer RJ, O'Connor DT:Exaggerated exocytotic adrenal medullary activity in response to stress inessential hypertension. Presented, ASCI, 1990. Clin Res 38(2): 477A, 1990.92. Takiyyuddin MA, Cervenka JH, Barbosa JA, Hsiao RJ, O'Connor DT:Pharmacologic dissociation of chromogranin A and catecholamines in man. ClinRes 38(2): 522A, 1990.93. Takiyyuddin MA, Barbosa JA, Casto RL, Printz MP, O'Connor DT:Overexpression of chromogranin A: a Mendelian trait that cosegregates withgenetic hypertension. ASN, 1990. JASN 1(4):501, 1991.94. Ford N, Natarajan C, Much D, Nichola P, Emans N, Swanson B, Cutler R,O'Connor DT, Sica D: Steady-state pharmacokinetics of fosinopril, enalapril,and lisinopril in patients with chronic renal insufficiency. ASN, 1990. JASN1(4):323, 1991.199195. Dimsdale JE, O'Connor DT, Ziegler M, Mills P: Chromogranin and sympatheticnervous system differences between blacks and whites. Presented, ASH, 1991.Am J Htn 4(5):78A, 1991.96. Parmer RJ, Petz LN, Rietow MG, Helman LJ, O'Connor DT: Humanchromogranin A is targeted to and released from regulated secretory vesicles inrat pheochromocytomacells. Presented, ASCI, 1991. Winner of the Henry Christian Award for ClinicalResearch, AFCR, 1991. Clin Res 39(2):172A, 1991.97. Takiyyuddin MA, DeNicola L, Kennedy B, Dinh TQ, Gabbai FB, Ziegler MG,O'Connor DT: Upregulation of a catecholamine storage vesicle protein in twokidney,one clip hypertension. Submitted, AFCR, 1991. Clin Res 39(2):433A,1991. Presented, American Heart Association Council for High Blood PressureResearch, September, 1991. Hypertension 18(3):417, 1991.98. Rozansky DJ, Wu HJ, Parmer R, O'Connor DT: Identification of 5' regulatoryregion for the rat chromogranin A gene. Presented, ASCI, 1991. Clin Res39(2):350A, 1991.99. Wu HJ, Rozansky DJ, Parmer RJ, Gill BM, O'Connor DT: Structure of themouse chromogranin A gene and tissue specificity of its promoter. Presented,ASCI, 1991. Clin Res 39(2):365A, 1991.100. Videen JS, O'Connor DT: Interactions of cations and proteins in catecholaminestorage vesicles. Presented, ASCI, 1991. Clin Res 39(2):365A, 1991.101. Parmer RJ, Stone RA, Cervenka JH, O'Connor DT: Renal hemodynamics inessential hypertension: racial differences in response to dietary salt. Presented,ASN, 1991. JASN 2(3):493, 1991.1992102. Sullivan PA; Grosch C, Lawless D, O'Connor DT: Short-term strenuousexercise training: effects on blood pressure and hormonal levels in mildhypertension. Ir-J-Med-Sci. 1992 Dec; 161(12):666-9.37

O'Connor, Daniel T.American Association of Immunologists.125. Le H, Kailasam MT, Cervenka JH, Wilson AF, and O'Connor DT and ParmerRJ. Sympathetic nervous system reactivity to cold stress in families withessential hypertension: Racial differences and evidence for heritability. Journalof the American Society of Nephrology, v.7, n.9, 1996:1552. Presented at the29th ASN Annual Meeting in New Orleans, LA. November 3-6, 1996.126. Parmer RJ, Le H, Kailasam MT, Wilson AF, and O'Connor DT. ImpairedBaroreflex sensitivity is associated with blood pressure elevation anddyslipidemia in families with essential hypertension. Journal of the AmericanSociety of Nephrology, v.7, n.9, 1996:1554. Presented at the 29th ASN AnnualMeeting in New Orleans, LA. November 3-6, 1996. Hypertension (Dallas), v.28,n.3, 1996.:509. Conference: 50th Annual Conference and Scientific Sessions ofthe Council for High Blood Pressure Research.127. Parmer, R. J.; Mahata, M.; Mahata, S.; Sebald, M. T.; O'Connor, DT.; Miles, L.A.. Tissue plasminogen activator (t-PA) is targeted to the regulated secretorypathway: Catecholamine storage vesicles as a reservoir for the rapid release oft-PA. Fibrinolysis, v.10, n.SUPPL. 3, 1996.:86. Conference: XIIIth InternationalCongress on Fibrinolysis and Thrombolysis.181. Wong CM, O'Connor DT, Martinez JA, Parmer RJ. Dysregulation of renalkallikrein responses to mineralocorticoid secretagogues in African-Americans.Journal of the American Society of Nephrology, v.7, n.9, 1996.:1557. Presentedat the 29 th ASN Annual Meeting in New Orleans, LA. November 3-6, 1996.1997129. Cubells, J. F.; Van Kammen, D. P.; Rao, P.; Kelley, M. E.; O'Connor, DT;Gelernter, J. CSF levels of dopamine beta-hydroxylase protein and alleles of theDBH gene in schizophrenic subjects. Society for Neuroscience Abstracts, v.23,n.1-2, 1997.:556. Conference: 27th Annual Meeting of the Society forNeuroscience, Part 1. American Journal of Human Genetics, v.61, n.4 SUPPL.,Oct., 1997.:A272. Conference: 27th Annual Meeting of the Society forNeuroscience, Part 1.130. Hoecker, Michael; Waigand, K.; Rosewicz, S.; O'Connor, DT; Riecken, E. O.;Wiedenmann, B.; Wang, T. C.. Gastrin regulates chromogranin A promoteractivity in AGS-B gastric carcinoma cells and transgenic mice. Gastroenterology,v.112, n.4 SUPPL., 1997.:A1155. Conference: Digestive Disease Week and the97th Annual Meeting of the American Gastroenterological Association.131. Kailasam, T.; Martinez, Joseph A.; Cervenka, Justine H.; Yen, Samuel S. C.;O'Connor, Daniel T.; Parmer, Robert J.. Racial differences in renalkallikrein excretion in ovulating females. Journal of the American Society ofNephrology, v.9, n.PROGRAM AND ABSTR. ISSUE, Sept., 1997.:317A.Conference: 30th Annual Meeting of the American Society of NephrologyPub type: BOOK; CONFERENCE LITERATURE; CHAPTER.132. Shen, Guoqiu; Trejo, Devin; Wu, Nancy; Lal, Navanit; O'Connor, DT.Comparison of native and recombinant chromogranin A antigens. Journal of theAmerican Society of Nephrology, v.9, n.PROGRAM AND ABSTR. ISSUE, Sept.,1997.:395A. Conference: 30th Annual Meeting of the American Society ofNephrology.1998133. Hoecker, Michael; Raychowdury, Raktima; Plath, Thoams; Wu, Hongjiang;O'Connor, Daniel T.; Wiedenmann, Bertram; Rosewicz, Stefan; Wang, TimothyC.. Sp1 and CREB mediate gastrin-dependent regulation of chromogranin A40

O'Connor, Daniel T.promoter activity. Digestive Diseases and Sciences, v.43, n.8, Aug., 1998.:1895.Conference: 12th International Symposium on Regulatory Peptides.Gastroenterology, v.114, n.4 PART 2, April 15, 1998.:A1150. Conference:Digestive Diseases Week and the 99th Annual Meeting of the AmericanGastroenterological Association.134. Kailasam, Mala T.; Diggle, Karin; Wilson, Alexander F.; O'Connor, Daniel T.;Parmer, Robert J. Linkage of alpha-adrenergic pressor responsiveness tochromosome 5q in hypertensive families. Journal of the American Society ofNephrology, v.9, n.PROGRAM AND ABSTR. ISSUE, Sept., 1998.:325A.Conference: 31st Annual Meeting of the American Society of Nephrology.Hypertension (Dallas), v.32, n.3, Sept., 1998.:593. Conference: 52nd Annual FallConference and Scientific Sessions of the Council for High Blood PressureResearch.135. Lewis, J.B.; Agodoa, L.; Cheek, D.; Greene, T.; Middleton, J.; O'Connor, D.;Wright, J.; (USA), AASK Study Group. Estimation of GFR from serum creatininein the African-American study of kidney disease and hypertension (AASK).Journal of the American Society of Nephrology, v.9, n.PROGRAM AND ABSTR.ISSUE, 1998.:153A. Conference: 31st Annual Meeting of the American Societyof Nephrology.136. Livsey, Carolyn V.; Taupenot, Laurent; Mahata, Sushil K.; Mahata, Manjula;O'Connor, Daniel T.. Formation of the catecholamine release-inhibitorypeptide catestatin by endogenous proteolytic cleavage of chromogranin A withincatecholamine storage vesicles: Determination of cleavage sites by massspectrometry. Hypertension (Dallas), v.32, n.3, Sept., 1998.:603. Conference:52nd Annual Fall Conference and Scientific Sessions of the Councilfor High Blood Pressure Research.137. Miller, Lucy M.; Tyrell, Elizabeth A.; Kailasam, Mala T.; Parmer, Robert J.;Gabbai, Francis B.; O'Connor, Daniel T.. Early alteration in glomerularresponse to amino acids in humans at genetic risk of essential hypertension.Journal of the American Society of Nephrology, v.9, PROGRAM AND ABSTR.ISSUE, Sept., 1998.:327A. Presented at the 31st Annual Meeting of theAmerican Society of Nephrology. Hypertension (Dallas), v.32, n.3, Sept.,1998.:602. Conference: 52nd Annual Fall Conference and Scientific Sessions ofthe Council for High Blood Pressure Research.138. Taupenot, L.; Mahata, M.; Mahata, S. K.; O'Connor, DT. Pituitary adenylylcyclase-activating polypeptide (PACAP) elicits dual desensitizing and extendedeffects on the activation of catecholamine (CA) secretion and chromogranin A(CgA) transcription in PC12 cells. Molecular Biology of the Cell, v.9, n.SUPPL.,Nov., 1998.:484A.Conference: 38th Annual Meeting of the American Society for Cell Biology139. Wright, Fred A.; O'Connor, Daniel T.; Yoneda, Lisa U.; Kutey, Greg; Roberts,Elizabeth; Berry, Charles; Weber, James; Timberlake, David; Schlager, Gunther.A genome scan for blood pressure loci in mice. Hypertension (Dallas), v.32, n.3,Sept., 1998.:594. Conference: 52nd Annual Fall Conference and ScientificSessions of the Council for High Blood Pressure Research.1999140. Kailasam, Mala T.; O'Connor, Daniel T.; Ward, Harry J.; Wilson, Alexander F.;Parmer, Robert J. Evidence for heritability of renal microalbumin excretion inessential hypertension. Journal of the American Society of Nephrology, v.10,n.PROGRAM AND ABSTR. ISSUE, Sept., 1999.:366A. Conference: 32ndAnnual Meeting of the American Society of Nephrology.41

O'Connor, Daniel T.141. Parmer, Robert J.; Song, Qing; Kailasam, Mala T.; O'Connor, Daniel T.; Chao,Julie; Chao, Lee. Renal kallikrein excretion is associated with allelic variation inthe human tissue kallikrein promoter on chromosome 19q in families withessential hypertension. Journal of the American Society of Nephrology, v.10,n.PROGRAM AND ABSTR. ISSUE, Sept., 1999.:368A. Conference: 32ndAnnual Meeting of the American Society of Nephrology.2000142. Rana, B.; Mills, P.; Ziegler, M.; Dimsdale, J.; O'Connor, D.; Parmer, R.; Insel, P.International Society of Hypertension. (18th Scientific Meeting of the InternationalSociety of Hypertension Chicago, Illinois, USA August 20-24, 2000). A searchfor polymorphisms associating with hypertension in the dopamine 1 receptorlocus coding region. In: Journal of Hypertension 2000. 18 (Suppl. 4): S180.143. Rao, Fangwen; Keiser, Harry R.; O’Connor, Daniel T. (33 rd Annual Meeting ofthe American Society of Nephrology and the 2000 Renal Week Toronto, Ontario,Canada. October 10-16, 2000). Malignant and benign pheochromocytoma:Chromaffin granule transmitter secretion and the response to chemotherapy. In:Journal of the American Society of Nephrology, September, 2000. 11 (Programand Abstract Issue): 353A.144. Ciraku, Ilirana; Kailasam, Mala T.; O’Connor, Daniel T.; Parmer, Robert J. (33 rdAnnual Meeting of the American Society of Nephrology and the 2000 RenalWeek, Toronto, Ontario, Canada. October 10-16, 2000). Renal aldosteroneexcretion predicts early renal injury in human essential hypertension. In: Journalof the American Society of Nephrology September, 2000. 11 (Program andAbstract Issue): 345A.2001145. P Mahboubi, MP Printz, SK Mahata, NR Mahapatra, RO Stuart, DT O’Connor.The neuroendocrine transcriptome: early, global changes in adrenal geneexpression in rodent genetic hypertension. Presented at Amer Heart AssnCouncil for High Blood Pressure Research, 55 th annual meeting, Chicago,September 22-5, 2001. In: Hypertension, 38(3): 496, 2001.146. NR Mahapatra, M Mahata, SK Mahata, DT O’Connor. Catecholamine storagevesicles: a dynamic cellular pool of calcium during exocytotic secretion?Quantitation of vesicular calcium concentration in living cells by expression of anovel targeted chromogranin A/aequorin (photoprotein) chimera. Presented atAmer Heart Assn Council for High Blood Pressure Research, 55 th annualmeeting, Chicago, September 22-5, 2001. In: Hypertension, 38(3): 521, 2001.147. SK Mahata, NR Mahapatra, M Mahata, TC Wang, DT O’Connor. Stimulustranscriptioncoupling during sympathetic outflow: a novel transgenicpromoter/photoprotein approach. Presented at Amer Heart Assn Council for HighBlood Pressure Research, 55 th annual meeting, Chicago, September 22-5, 2001.In: Hypertension, 38(3): 508, 2001.148. M Mahata, NR Mahapatra, DT O’Connor, SK Mahata. Novel, potent effects ofthe gastrointestinal peptide secretin to stimulate catecholamine andcatecholamine secretory vesicle protein gene expression in chromaffin cells.Presented at Amer Heart Assn Council for High Blood Pressure Research, 55 thannual meeting, Chicago, September 22-5, 2001. In: Hypertension, 38(3): 508,2001.149. L Taupenot, KL Harper, NR Mahapatra, DT O’Connor. Intracellular proteintrafficking into catecholamine storage vesicles: novel chimeric photoproteinsvisualized by deconvolution fluorescence microscopy. Presented at Amer Heart42

O'Connor, Daniel T.Assn Council for High Blood Pressure Research, 55 th annual meeting, Chicago,September 22-5, 2001. In: Hypertension, 38(3): 508, 2001.150. DT O’Connor, M Kailasam, BP Kennedy, MG Ziegler, N Yanaihara, RJ Parmer.Early decline in the catecholamine release-inhibitory peptide catestatin inhumans at genetic risk of hypertension. Presented at Amer Soc Nephrol/ ISNWorld Congress of Nephrology, 2001 annual meeting, San Francisco, October10-17, 2001. In: Journal of the American Society of Nephrology September,2001. 12 (Program and Abstract Issue): 488A.151. PE Cadman, F Rao, SK Mahata, DT O’Connor. The dysglycemic hormonepancreastatin is active in humans in vivo. Presented at Amer Soc Nephrol/ ISNWorld Congress of Nephrology 2001 annual meeting, San Francisco, October10-17, 2001. In: Journal of the American Society of Nephrology September,2001. 12 (Program and Abstract Issue): 480A.152. T Shiina; BK Rana; MG Ziegler; DT O’Connor; PA Insel. Identification andcharacterization of a novel 5’UTR SNP in the human dopamine recepor D1 gene.Presented at the Scientific Sessions 2001 of the American Heart AssociationAnaheim, CA, USA November 11-14, 2001. In: Circulation October 23, 2001.104 (17 Supplement): II.145.153. Jiang, Q.; Taupenot, L.; Mahata, S. K.; Mahata, M.; O'Connor, D. T.; Miles, L.A.; Parmer, R. J.. A novel mechanism for the regulation of catecholaminerelease: Processing of chromogranin A (CgA) by plasmin. Presented at AmerSoc Nephrol/ ISN World Congress of Nephrology, 2001 annual meeting, SanFrancisco, October 10-17, 2001. In: Journal of the American Society ofNephrology. 12(Program and Abstract Issue). September, 2001. 569A.2002154. L. Taupenot, K. Harper, NR Mahapatra, RJ Parmer, S.K Mahata, DT O’Connor.Intracellular Protein Trafficking into Catecholamine Storage Vesicles:Identification of a Novel Sorting Determinant in the Secretory ProteinChromogranin A. Presented at Amer Heart Assn Council for High BloodPressure Research, 56th annual meeting, Orlando, Florida, September 25-28,2002. In: Hypertension, 40(3): 408, 2002.155. SK Mahata, NR Mahapatra, M. Mahata, TC Wang, DT O’Connor.Chromogranin A: A Nexus of Nicotinic Signaling to Catecholamine Secretion andGene Transcription In Viivo. Presented at Amer Heart Assn Council for HighBlood Pressure Research, 56th annual meeting, Orlando, Florida, September25-28, 2002. In: Hypertension, 40(3): 409, 2002.156. M. Mahata, NR Mahapatra, DT O’Connor, SK Mahata. Secretin Signaling toCatecholamine Secretion and Catecholamine Secretory Vesicle Protein GeneTranscription in Chromaffin Cells. Presented at Amer Heart Assn Council forHigh Blood Pressure Research, 56th annual meeting, Orlando, Florida,September 25-28, 2002. In: Hypertension, 40(3): 409, 2002.157. NR Mahapatra, M. Mahata, DT O’Connor, SK Mahata. Novel Cocaine effectson Catecholamine Secretion: Signaling and Interaction with Neuronal Nicotinic-Cholinergic Receptor. Presented at Amer Heart Assn Council for High BloodPressure Research, 56th annual meeting, Orlando, Florida, September 25-28,2002. In: Hypertension, 40(3): 409, 2002.158. F. Rao, PE Cadman, G. Zhang, DT O’Connor. Heredity and Autonomic controlof the circulation in Humans: Quantification by Non-Invasive Studiies in Twins.Presented at Amer Heart Assn Council for High Blood Pressure Research, 56thannual meeting, Orlando, Florida, September 25-28, 2002. In: Hypertension,40(3): 4024, 2002.43

O'Connor, Daniel T.2003159. Mahapatra, Nitish R.; Mahata, Manjula; O'Connor, Daniel T.; Mahata, Sushil K.Secretin activation of chromogranin A gene transcription: identification of thesignaling pathways in cis and in trans. FASEB, 2003. FASEB Journal. 17(4-5):851.12, March 2003.160. Mahata, Sushil K.; Mahapatra, Nitish R; Mahata, Manjula; O'Connor, Daniel T.Cocaine-catestatin (chromogranin A344-364) co-actions: inhibition of nicotiniccholinergicstimulation of catecholamine secretion and gene transcription.FASEB, 2003. FASEB Journal. 17(4-5):851.8, March 2003.161. Mahboubi, Payam; Fries, Ryan S.; Printz, Morton P.; Mahata, Sushil K.;Mahapatra, Nitish R.; Stuart, Robert O.; Schmid-Schonbein, Geert W.;O'Connor, Daniel T. The neuroendocrine transcriptome: early, global changesin adrenal gene expression in rodent genetic hypertension. FASEB, 2003.FASEB Journal. 17(4-5):659.3, March 2003.162. Tang, Chih-Min; Zheng, Bin; O'Connor, Daniel T; Wiley, James S.; Farquhar,Marilyn G.; Insel, Paul A. Identification of single nucleotide polymorphisms inRGS-PX, novel proteins that function as negative regulators for heterotrimericGTP-binding proteins (G proteins). FASEB, 2003. FASEB Journal. 17(4-5):145.7, March 2003.163. Chandran, Rubin; Rao, Fangwen; Cadman, Peter E.; Chen, Alice Y.; Nguyen,Kathy; Bolotnikova, Anna; Zhang, Guangfa; Rana, Brinda K.; Insel, Paul A.;Schork, Nicholas A.; O'Connor, Daniel T. Human pressor responses:Heritability estimations in twins, and genotypic associations at adrenergic andrenin/angiotensin loci. Amer Soc Hypetension, 2003. American Journal ofHypertension. 16(5 Part 2):80A, May 2003.164. Lee, Jean C.; Taylor, Carolyn V.; Gaucher, Sara P.; Toneff, Thomas; Taupenot,Laurent; Yasothornsrikul, Sukkid; Mahata, Sushil K.; Sei, Catherine; Parmer,Robert J.; Neveu, John M.; Lane, William S.; Gibson, Bradford W.; O'Connor,Daniel T.; Hook, Vivian Y. H. Primary sequence characterization of catestatinintermediates and peptides defines proteolytic cleavage sites utilized forconverting chromogranin A into active catestatin secreted from neuroendocrinechromaffin cells. Molecular & Cellular Proteomics. 2(7 Supplement):S54, July2003.165. Wen, G.; Mahata, S. K.; Cadman, P.; Mahata, M.; Ghosh, S.;Mahapatra, N. R.; Rao, F.; Stridsberg, M.; Smith, D. W.; Mahboubi,P.; O'Connor, D. T.; Hamilton, B. A. Human chromogranin A(CHGA): Discovery of both frequent and rare functionalpolymorphisms at a locus governing catecholamine storage andrelease. Amer Soc Hum Genet, 2003. American Journal of HumanGenetics. 73(5):393, November 2003.2004166. Ho, H.; Hall, S. D.; Flockhart, D. A.; Li, L.; Skaar, T.; Cadman, P.;O'Connor, D. T. The association between CYP3A5 genotype andantihypertensive response. ASCPT, 2004. Clinical Pharmacology &Therapeutics. 75(2):P62, February 2004.167. Zhang, Lian; Rao, Fangwen; King, Danuta; Chandran, Rubin;Wessel, Jennifer; Rana, Brinda K.; Kennedy, Brian P.; Zhang,Guangfa; Ziegler, Michael G.; Schork, Nicholas J.; O'Connor, DanielT. Autonomic nervous system activity (baroreflex sensitivity):Prediction by polymorphism at the tyrosine hydroxylase (TH) locus,44

O'Connor, Daniel T.the rate-limiting enzyme in catecholamine biosynthesis. Amer SocHypertension, 2004. American Journal of Hypertension. 17(5, Part2):80A, May 2004.168. Rao, Fangwen; King, Danuta; Wessel, Jennifer; Schork, Nicholas J.;O'Connor, Daniel T. Beta-adrenergic control of human heart ratevariability (HRV): Prediction by multiple single nucleotidepolymorphisms (SNPS) at the beta-2 (ADRB2) though not the beta-1(ADRB1) adrenergic receptor genetic loci. Amer Soc Hypertension,2004. American Journal of Hypertension. 17(5, Part 2):79A-80A, May2004.2005.169. King, Danuta; Etzel, Jason; Chopra, Shagun; Smith, Joshua;Cadman, Peter E.; Rao, Fangwen; Funk, Stephen D.; Rana, BrindaK; Schork, Nicholas J.; Insel, Paul A.; and O’Connor, Daniel T.Human response to 2-adrenergic agonist stimulation studied in anisolated vascular bed in vivo: biphasic influence of dose, age,gender, and receptor genotype. ASCPT 2005. Clinical Pharmacologyand Therapeutics 2005. Vol 77, Number 2: P5, February 2005.170. Le Corre, Pascal; Parmer, Robert; Kailasam, Mala; Kennedy, Brian;Skaar, Todd; Ho, Herbert; Leverge, Roger; Smith, Douglas; Ziegler,Michael; Insel, Paul; Schork, Nicholas; Flockhart, David; andO'Connor, Daniel T. Human sympathetic activation by adrenergicblockade with yohimbine: Bimodal, epistatic influence ofcytochrome P450-mediated drug metabolism. ASCPT 2005. ClinicalPharmacology and Therapeutics 2005. Vol 77, Number 2: P6,February 2005.171. Rao, Fangwen; Wen, Gen; Mahata, Sushil; Kennedy, Brian;Stridsberg, Mats; Abel, Kenneth; Smith, Douglas; Eskin, Eleazar;Schork, Nicholas; Hamilton, Bruce; Ziegler, Michael; and O’Connor,Daniel T. The Catecholamine Release Inhibitory Peptide Catestatin(Chromogranin A [CHGA]352-372): A Naturally Occurring AminoAcid Variant (Gly364Ser) Causes Profound Alterations In HumanAutonomic Activity. ASCPT 2005. Clinical Pharmacology andTherapeutics 2005. Vol 77, Number 2: P6, February 2005.172. Zhang, Lian; Rao, Fangwen; Wessel, Jennifer; Kennedy, Brian;Rana, Brinda; Taupenot, Laurent, Lillie, Elizabeth O., Cockburn,Myles; Schork, Nicholas J.; Ziegler, Michael G.; and O’Connor,Daniel T. Functional allelic heterogeneity and pleiotropy of a repeatpolymorphism in tyrosine hydroxylase: Prediction of catecholaminesand response to stress in twins. ASCPT 2005. Clinical Pharmacologyand Therapeutics 2005. Vol 77, Number 2: P6, February 2005.173. Mahata, Sushil; Mahata, Manjula; Wen, Gen; Wong, William;Mahapatra, Nitish; Hamilton, Bruce; and O’Connor, Daniel T. TheCatecholamine Release-Inhibitory “Catestatin” Fragment ofChromogranin A: Naturally Occurring Human Variants with DifferentPotencies for Multiple Chromaffin Cell Nicotinic CholinergicResponses. ASCPT 2005. Clinical Pharmacology and Therapeutics2005. Vol 77, Number 2: P6, February 2005.174. Etzel, Jason; Rana, Brinda; Wen, Gen; Parmer, Robert; Schork,Nicholas; O’Connor, Daniel T. Genetic Variation at the Human45

O'Connor, Daniel T.α2B-Adrenergic Receptor Locus: Role in Blood Pressure Variationand Yohimbine Response. ASCPT 2005. Clinical Pharmacology andTherapeutics 2005. Vol 77, Number 2: P7, February 2005.B. UNPUBLISHED MATERIAL.19771. O'Connor DT, Weismann M, Fierer J: Hypocomplementemia andthrombocytopenia in Staph. aureus endocarditis. Presented, Am Soc Microbiol.1977.19782. O'Connor DT, Stone RA, Preston RA, Mitas JA, Wall J: Race and hypertension:etiologic differences and response to therapy. Presented, National Med Assoc,1978.19813. O'Connor DT, Frigon RP, Sokoloff RL: Human catecholamine storage vesicleproteins. Presented, Hypertension SCOR National Meeting, 1981.4. Insel PA, Motulsky HJ, O'Connor DT, Snavely MD: Changes in adrenergicreceptors in experimental and human hypertension. Presented, HypertensionSCOR National Meeting, 1981.19825. O'Connor DT, Frigon RP: Chromogranin A, a new probe of sympathoadrenalfunction: Quantification by radioimmunoassay. Presented, Am Heart AssocCouncil for High Blood Pressure Research, 1982.19836. O'Connor DT, Burton D, Deftos LJ: Human chromogranin A: detection byimmunohistology in diverse polypeptide hormone producing tumors. Presented,Endocrine Society, 1983.7. See 1982 #5 in this section19848. O'Connor DT, Bernstein KN: Human chromogranin A, the major catecholaminestorage vesicle soluble protein: purification and characterization from CSV ofpheochromocytoma, quantitation by radioimmunoassay, and evaluation inplasma as an index of sympathoadrenal activity in normal and hypertensive man.Presented, Symposium on Neuropeptides/Blood Pressure Control, Heidelberg,1984; International symposium on Molecular Biology of PeripheralCatecholamine Storing Tissues, Colmar, France, 1984; International Society ofHypertension, Switzerland, 1984; Am Heart Association Council for High BloodPressure Research, 1984.9. O'Connor DT, Deftos LJ: Chromogranin A: Ubiquitous production by normaland neoplastic peptide producing endocrine tissues, revealed byradioimmunoassay and immunohistology. Presented, International symposiumon Molecular Biology of Peripheral Catecholamine Storing Tissues, Colmar,France, 1984.198510. Mezger MS, O'Connor DT: Plasma chromogranin A in subjects with renalfailure: elevations from both degree of renal insufficiency and secondaryhyperparathyriodism. Presented, XXII Congress of EDTA/European RenalAssociation, 1985.46

O'Connor, Daniel T.11. Deftos LJ, O'Connor DT, Carney DN, Linnoila RI, Gazdar AF: Chromogranin Ais expressed in cell lines from small cell lung carcinomas having neuroendocrineproperties. Presented, Endocrine Soc, 1985.12. Deftos LJ, O'Connor DT: Chromogranin A is co-secreted with bone-activepeptides and other hormones in humans. Submitted, Am Soc for Bone andMineral Research, 1985.13. Kitt CA, Walker LC, Struble RG, Price DL, Johss TH, Wainer BH, O'Connor DT:Distribution of monoamines in monkey hippocampus. Presented, Soc. forNeurosci, 1985.14. Struble RG, Powers RE, Casanova MF, Kitt CA, O'Connor DT, Price DL:Multiple transmitter-specific markers in senile plaques in Alzheimer's Disease.Submitted, Soc for Neurosci, 1985.15. Parmer RJ, O'Connor DT: Enkephalins in pheochromocytoma: RIA andchromatographic identification, chromaffin granule localization, and precursorcharacterization. Presented, 2nd annual Marion Hypertension Research ClinicalFellowship Program, 1985.198616. Deftos LJ, Murray S, O'Connor DT, Delegeane AM, Mellon P: A clonedchromogranin A cDNA detects a 2.3 Kb mRNA in diverse neuroendocrinetissues. Submitted, Endocrine Society, 1986.17. O'Connor DT, Deftos LJ (spon: SJ Manolagas): Endocrine neoplasia secretechromogranin A along with their characteristic resident peptide hormones.Submitted, Endocrine Society, 1986 (not presented).18. Jengeleski CA, Powers RE, O'Connor DT, Price DL: Noradrenergic innervationof the human pineal gland in aging and Alzheimer's Disease. Submitted, Soc forNeurosci, 1986.19. O'Connor DT, Deftos LJ: Endocrine neoplasia secrete chromogranin A alongwith their characteristic resident peptide hormones. Presented, NY Acad SciConference on the Cellular and Molecular Biology of Hormone andNeurotransmitter Containing Secretory Vesicles, 1986.20. O'Connor DT, Parmer RJ, Serck-Hanssen G, Deftos LJ, Murray S, Burton D,Delegeane A, Mellon P: Chromogranin A: studies of its secretion, size forms,and molecular biology. Presented, NY Acad Sci Conference on the Cellular andMolecular Biology of Hormone and Neurotransmitter Containing SecretoryVesicles, 1986.198721. Parmer RJ, Handa M, O'Connor DT: Detection of putative chromogranin clonesfrom a rat adrenal chromaffin cell cDNA library. Presented, Am SocHypertension, 1987.198822. Stoddard S, O'Connor DT, Tyce GM, Yaksh TL, Carmichael S: The secretion ofcatecholamines, chromogranin A, and neuropeptide Y from the feline adrenalmedulla in situ. Presented, Am Assoc Anatomists, 1988.23. Nanes MS, O'Connor DT, Marx SJ; Chromogranin A in primaryhyperparathyroidism. Presented, Endocrine Society, 1988.24. Bakhit C, Koda L, Benoit R, Randolph L, O'Connor DT, Bloom FE: Effects ofcysteiamine on catecholamines and somatostatin-14 in rat brain.25. O'Connor DT, Parmer RJ, Koop AH, Wu HJ, Gill BM: Chromaffin cell secretoryproteins: molecular biological approaches to their structure and function.Presented, 9th Annual UCSD Neurosciences Information Exchange, 1988.198926. Rogers PJ, Tyce GM, Weinshilboum RM, O'Connor DT, Bove AA:Catecholamine metabolic pathways and exercise training: plasma and urine47

O'Connor, Daniel T.catecholamines, metabolic enzymes, and chromogranin A. Presented, Am. Coll.Cardiol., 1989.199027. To BBC, Ito MK, O'Connor DT: Comparative pharmacokinetics of transdermalclonidine: the effects of dermal pretreatment with hydrocortisone cream ormagnesium-aluminum hydroxide suspension. Presented at Western statesconference for pharmacy residents, fellows and preceptors, 1990.28. Shults CW, Goetz C, Klawans HL, Carvey PM, Watts RL, Bakay RL, U HS,Gage FH, O'Connor DT: Transplantation of the adrenal medulla to the caudatein Parkinsonian patients does not cause an increase in ventricular fluidchromogranin A. Presented, Am. Acad. Neurol., 1990.29. Gratzl M, Lahr G, Heiss C, Mayerhofer C, Schilling K, Parmer RJ, Pilgrim C,O'Connor DT: Chromogranin A in the olfactory system of the rat. Presented,Society for Neuroscience, 1990.30. Wand GS, O'Connor DT, Takiyyuddin MA, Levine MA: A proposed role forchromogranin A as a glucocorticoid-responsive autocrine inhibitor of ACTHsecretion. Presented, Endocrine Society, 1990.31. Blind E, Schmidt-Gayk H, Raue F, Ziegler R, O'Connor DT: Chromogranin A inmedullary thyroid carcinoma. American Society for Bone and Mineral Research,1990.199132. O'Connor DT. Chromogranin A: from gene to organism. InternationalSymposium on Chromaffin Cell Biology, Marburg, Germany, August, 1991.199233. O'Connor DT: The chromogranins: diagnostic value in hypertension andfunctional implications for catecholamine storage and release. Presented(plenary lecture), ASH, May, 1992.48